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CHAPTER I 
 
SYSTEMS BIOLOGY AND THE STUDY OF METABOLISM 
 
Systems biology is a field of science that is based on the exploration of the  
dynamics of complete biological entities by describing the interactions between all the 
components.1,2  Systems biology arose out of the realization that the vast amount of 
genomic and proteomic data being discovered needed to be examined in a integrated 
manner.  The goal of systems biology is to define the properties, relationships and 
functions of a biological system.  Figure 1 illustrates the hierarchy of scales involved in 
biology from molecules to whole animals.3  
 
 
Figure 1.  Hierarchical scales of biology3 
 
The field of genomics began with the sequencing of entire genomes in the 1980s,2 
and proteomics is focused on the structure and function of proteins encoded in the DNA.3  
Recent studies attempting to discover genes involved in disease have been almost too 
2 
sensitive, discovering that thousands of genes can change expression during the 
progression of cancer.4,5  In another study, 600 out of 9600 genes studied all showed 
correlation with the aggressiveness of lung cancer;6 however, it is not known which of 
these genes has a functional impact.  As the rate that genes are being sequenced 
increases, the emphasis is being shifted to the function of genes.  To some degree this can 
be studied with proteomics, as there is a clear link between gene sequence and protein 
structure.  Yet, protein sequence alone cannot give a great deal of information about 
function.  In most cases, the protein function can be derived from the phenotype7 and 
these studies examine proteins outside of their cellular context.3   
In addition to genomics and proteomics, there is an ever-expanding taxonomy of 
additional “omics” fields, including the transcriptome, glycome, and metabolome.8  The 
term “metabolome” has been coined to describe the entire metabolic composition of an 
organism or cell.3,9,10 While some view metabolomics as a subset of metabonomics,10 
others view the terms as interchangeable. According to Fiehn in his 2001 review, 
metabolomics is the “comprehensive and quantitative analysis of all metabolites.”11 
Metabonomics is very similar and is defined as “the quantitative measurement of the 
time-related multi-parametric metabolic response of living systems to pathophysiological 
stimuli or genetic modification.”12  However, from a practical standpoint, metabolomics 
deals with metabolic regulation and fluxes of individual cells or cell types.  
Metabonomics is the study of biochemical profiles of whole organisms and is typically 
studied using biofluids, such as blood or urine, or cell or tissue extracts.3,10,13  The greatest 
impact of metabonomics has been in the area of toxicology, particularly preclinical 
toxicology, and the search for biomarkers.8  
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The main approaches currently in use for analysis of the metabolome are nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) methods.7,8,10,13  
Typically, MS methods are used in conjunction with a pre-separation of the metabolites 
using gas chromatography (GC), liquid chromatography (LC), high-pressure liquid 
chromatography (HPLC), or ultra-high-pressure liquid chromatography (UHPLC).  MS 
has been widely used in metabolic fingerprinting and metabolite identification studies.13 
As Robertson points out, “MS excels at selective identification of a molecular entity, 
while NMR excels at the identification of all proton containing species in a sample.”  
However, “specific platforms are not a prerequisite for metabonomic investigation.”8  
Thus, the method best suited for a given study is dictated by the type of information 
desired.  
Typically, 1H spectra of biofluids contain thousands of signals that arise from the 
hundreds of molecules present that represent many biological pathways.10  This complex 
signal can  be used to monitor increases or decreases in a particular signal as a result of a 
biological pathway as the signal intensity is dependent on the concentration in solution.  
More advanced two dimensional NMR methods, such as correlation spectroscopy 
(COSY), can be used to increase signal dispersion and elucidate the connectivity between 
signals.7  An additional advantage of NMR is that intact tissues can be studied without 
pretreatment using magic angle spinning (MAS).  The term “magic angle” is derived 
from phenomenon that when a sample is spun rapidly (~4-6 kHz) at an angle of 54.7° 
relative to the applied magnetic field the line-broadening effects that would normally 
obscure the proton spectra of a solid sample are greatly reduced.8,10,13 
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All metabolomic and metabonomic studies result in complex data sets that require 
“chemometric and biometric methods for interpretation and production of biochemical 
fingerprints that are of diagnostic or other classification value.”13  A number of 
approaches have been developed to model metabolism, such as structural, stoichiometric 
and carbon flux models, stationary and non-stationary mechanistic models, and models 
with gene regulation.  The flux of carbon and electrons under varying conditions can be 
estimated by stoichiometric models of enzyme pathways and measurable quantities of 
metabolites.3   Metabolic flux analysis (MFA) determines the carbon fluxes in central 
carbon metabolism and related pathways based on measurement of extracellular rates, 
assuming pseudo steady state and a stoichiometric model of metabolism.14,15  MFA can 
provide insights into cellular metabolism under varied bioreactor conditions and rapidly 
clarify the cellular response to culture conditions.  MFA experiments are limited to large 
numbers of cells in bioreactors or well-plates and are on a long term timescale but 
without continuous measurement.15  Most studies use either a stoichiometric approach or 
isotope tracer approach to estimate intracellular fluxes, and the metabolic fluxes are 
computed offline after analysis of nutrient and metabolite levels or isotopic tracer 
concentrations.15 Isotopically labeled metabolites in 13C tracer experiments can be 
analyzed ex situ using either NMR or mass spectrometry to determine the labeling 
pattern.14,15 The offline nature of MFA measurements cause no real-time information to 
be obtained about the pathways effected.15   
A number of interesting physiological systems have extremely complex temporal 
behavior such as the cell cycle, circadian rhythm, and oscillations in glucose, insulin, and 
calcium by pancreatic islets.3  The development of other “omic” fields such as genomics 
5 
and proteomics were preceded by new instrumentation in electrophoresis and MS.  In the 
same manner, new methodologies are necessary in the field of metabolomics to 
accurately model metabolism as a dynamic process.  This dissertation centers on the 
development of an instrument that gathers dynamic real-time information on cellular 
metabolic processes, which we have named the multianalyte microphysiometer (MAMP). 
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CHAPTER II* 
 
DEVELOPMENT OF THE MULTIANALYTE MICROPHYSIOMETER 
 
The multianalyte microphysiometer (MAMP) has been used to measure the 
metabolic effects of fluoride, dinitrophenol, and antimycin A16 and applied to cancer 
studies of hypoxia and proliferation.17 Currently, the MAMP simultaneously measures the 
extracellular concentration of four analytes involved in cellular metabolism and was 
developed through modifications of an existing instrument, the Cytosensor® 
microphysiometer.16-20  
The Cytosensor microphysiometer, released by Molecular Devices in 1990, uses 
a light addressable potentiometric sensor (LAPS) to study cellular metabolism by 
measuring changes in the extracellular acidification rate (ECAR).21  The Cytosensor® has 
been used to study many biological processes such as receptor pharmacology,22,23 enzyme 
modulators,24 cytotoxins,25 ionophores,26 immune effectors,27 and metabolic effectors.28  
The Cytosensor’s LAPS forms the lower surface of the microfluidic chamber and 
is comprised of a silicon semiconductor chip coated with a thin insulating layer of silicon 
oxynitride.  Chips are formed by first growing a 30 nm SiO2 film followed by low 
pressure chemical vapor deposition of Si3N4.29,30  Hydration of the insulating surface 
creates silanol and silamine groups on the surface, as shown in Figure 2.31 These groups  
 
 
*Eklund, S. E.; Snider, R. M.; Wikswo, J. P.; Baudenbacher, F.; Prokop, A.; Cliffel, D. E. J. Electroanal. Chem. 
2006, 587, 333-339. 
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Figure 2. Titration of silanol and silamine insulating layer of LAPS at high and low pH.  
At high pH the surface potential of the insulating layer is increased causing electrons to 
migrate toward the bulk silicon and holes toward the surface.31  
 
 
 
are titrated as the pH of the aqueous media changes, causing the surface potential of the 
insulating layer to shift by ~61 mV per pH unit at 37 °C.21,29,30,32  This change is in 
accordance with Nernst’s Law, as shown by the calculation below where the only change 
in the system is an increase in the acidity of the solution from pH 7 to pH 6.33 
€ 
Ecell = Ec −Ea  2H+ +2e-← →  H2
Ea =  Ea° + RTnF ln
H+[ ] 2
p H2( )
ΔEa =  Ea(pH6) −  Ea(pH7)
= RTF ln
1x10−6 M( )
1x10−7 M( ) =
8.314  J mol−1 K −1 •310K
96485 C ln10
= 61.5 mV
 
The LAPS is an n-type silicon semiconductor, which is formed when silicon is 
doped with an element whose valence electron energy closely matches the energy level of 
the conductance band, such as arsenic. In this case, at room temperature, the majority of 
donor atoms are ionized with each giving an electron in the conductance band and a 
corresponding positive site, or hole, in the donor atom.  When an interface is formed 
between an n-type semiconductor and an electrolyte, a space charge region forms in the  
8 
 
Figure 3. The formation of a junction between an n-type semiconductor and a solution 
containing a redox couple O/R. (a) Before contact in the dark. Typical values for energy 
levels shown referenced to NHE (E0) and to vacuum (E). (b) After contact in the dark and 
electrostatic equilibration, (c) Junction under irradiation. [Adapted from Bard]33  
 
 
 
semiconductor at the interface causing the band energies of the semiconductor to become 
more negative with increasing distance into the semiconductor, an effect known as “band 
bending.”  When this is illuminated by light with energy higher than the band gap of the 
semiconductor, photons are absorbed and electron-hole pairs are formed.  The space 
charge region promotes the separation of these pairs, with electrons moving into the bulk 
material and holes toward the surface, where they promote photo-oxidation and a 
photoanodic current.  Figure 3 illustrates the energy levels of an n-type semiconductor 
alone, in contact with an electrolyte solution in the dark, and in contact with an 
electrolyte solution when illuminated.33 
In the LAPS, a voltage is applied to the insulating layer by placing an electrode in 
the aqueous solution and attaching another electrode to the bare silicon surface, 
producing an electric field within the insulating layer and at the silicon-insulator  
9 
 
Figure 4. Schematic of the circuitry of the LAPS sensor of the Cytosensor.  The LED is 
infrared and modulated at 10 kHz.31,32 
 
 
 
interface.21,31 A schematic of the LAPS and its corresponding circuitry is given in Figure 
4.31,32 In this case, a 10 kHz modulated infrared LED is pulsed on the back of the silicon 
sensor, and the magnitude of the photocurrent depends on the magnitude of the electric 
field, which in turn is the sum of  both the applied potential and the surface potential of 
the insulating layer.30,31,34,35  As shown in Figure 5, the photocurrent-applied  
 
 
 
Figure 5. Photocurrent-voltage curves in LAPS and the effects of pH. The potential from 
solution to the silicon bulk was swept from -200 to + 800 mV while the light intensity 
was modulated at 10 kHz and the photocurrent was recorded. The curves represent pH 
4.0 (circles), pH 7.0 (diamonds), and pH 10.0 (squares). [Adapted from Owicki]30 
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potential curves generated at the LAPS change as the pH of the solution on the top of the 
LAPS changes.30  Thus to obtain a constant photocurrent with changing pH and changing 
surface potential, the applied potential must be adjusted.21,29-32,34 
There are multiple layers to the LAPS data in the Cytosensor; Figure 6 shows the 
hierarchy of this data.30  The potential applied across the silicon chip is scanned, and the 
photocurrent measured to obtain the initial level of data.  The applied potential at the 
inflection point of the photocurrent curve, Ψpip, is reported to the user as the raw data in 
the Cytosensor software at 1 Hz.  The rate of change in Ψpip is reported in –µV/s and is 
referred to as the ECAR.30,31   
 
 
 
Figure 6. Cytosensor data-analysis hierarchy. (a) The photoresponse curve (solid line).  
The inflection point of the photoresponse curve (Ψpip) is determined by finding the zero 
crossing of the second derivative (dashed line). (b) Ψpip is plotted versus time as the 
surface potential shifts its value. (c) The rate of change in the surface potential is 
determined by a least-squares fit.30 
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A cross-sectional view of the Cytosensor sensor chamber is depicted in Figure 7.17  
The cells used in Cytosensor experiments typically are seeded the night prior the 
experiment into Corning Costar® Transwell® tissue culture treated 3 µm pore 
polycarbonate membrane capsule cups with total area of 1.12 cm2.  Cells are seeded at a 
density 3-5 x 105 cells/capsule cup, such that the cells will be 75-80% confluent.  A 
spacer is placed atop the cells to help define the chamber volume and limit the area of 
cells exposed to 25% of the total area.  An additional 3 µm pore polycarbonate membrane 
insert is placed on top of the spacer.  The cells are placed atop the LAPS, which forms the 
lower surface of the sensor chamber. The sensor head, which contains fluid tubes and the 
counter electrode of the LAPS, is clamped down on top by a gantry with the o-ring 
defining the chamber height of ~100 µm and ~3 µL volume as well as creating electrical 
contact between the sensor head and the LAPS. 
 
 
 
Figure 7.  Cross sectional view of the sensor chamber of the Cytosensor showing the 
LAPS, LED, cells (trapped between two 3 µm pore membranes), spacer, and sensor 
head.17 
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In order to allow acidic byproducts of cellular metabolism such as lactic acid and 
carbonic acid to accumulate, lowering of the pH of the media, the Cytosensor is designed 
around a stop flow cycle of 120 s with 80 s of flow at 100 µL/min and 40 s of stop flow.  
The media used in the Cytosensor is weakly buffered (1 mM phosphate) in order to allow 
greater sensitivity.  As designed, changes measured in ECAR are correlated to changes in 
the metabolic activity of the cells.31 However, protons are only one of many chemical 
species involved in cellular metabolism, as seen in Figure 8. Also, the proton 
concentration is affected by changes in both anaerobic metabolism, through lactic acid, 
and aerobic metabolism through the production of carbon dioxide.17 In order to draw 
conclusions about the effect of a molecule of interest on cellular activity, information on 
more metabolic parameters is needed.  The MAMP was developed from the Cytosensor 
by the inclusion of electrochemical sensors for extracellular glucose, lactate, and 
oxygen.16-19 A more complete picture of cellular metabolism can be obtained with glucose 
and oxygen as input parameters and lactate and acidification as output parameters. 
 
 
 
Figure 8.  Illustration of glycolysis highlighting glucose, oxygen, lactate, carbon dioxide, 
and protons.17  
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To measure these three new analytes, the sensor head was modified by adding 
four platinum electrodes, one of which acts as the secondary counter electrode.  Four 0.6 
mm paths are drilled through the sensor head with the hole for the counter electrode 
widened on the surface to ~2 mm.  The counter electrode is made by melting a 0.5 mm 
platinum electrode to form a 1.5 mm ball at the end.  Two of the working electrodes are 
0.5 mm platinum wires used for glucose and lactate measurements.  The third working 
electrode, used to measure oxygen, is a 127 µm platinum wire, which is wrapped multiple 
times around a 0.5 mm platinum wire for added mechanical stability, with silver epoxy 
used to aid the electrical contact between the two.  Each wire is embedded in the sensor 
head with white epoxy, ground down flush to the face of the sensor head using silicon 
carbide grinding paper, and polished with 1 µm diamond paste.  The wires extending 
from the sensor head are reinforced with copper socket pins to add mechanical strength. 
Additional electrodes of different size or made of another material can be added. The 
surface of a modified sensor head, shown in Figure 9, is cleaned with water and ethanol, 
and the electrodes cleaned electrochemically by cycling in 0.5 M sulfuric acid.  
 
 
Figure 9.  Modified sensor head with one 1.5 mm (A), one 127 µm (B), and two 0.5 mm 
platinum electrodes (C and D). 
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Glucose, lactate, and oxygen are all measured amperometrically using the counter 
electrode on the modified sensor head and the reference electrode of the Cytosensor at a 
low frequency, to help prevent cross-talk with the high frequency measurement of the 
LAPS.  Oxygen is detected through direct reduction at the 127 µm electrode at – 0.45 V 
vs. Ag/AgCl (2 M KCl).  Glucose and lactate are measured indirectly through oxidation 
of hydrogen peroxide produced through the reaction of glucose oxidase (GOx) and lactate 
oxidase (LOx) enzymes at + 0.6 V vs. Ag/AgCl (2 M KCl), as shown in Figure 10.  GOx 
and LOx films are formed by hand casting onto the electrode surface a solution of the 
enzyme, bovine serum albumin (BSA), and glutaraldehyde.  A thin layer of Nafion 
(perfluorosulfonic acid-PTFE copolymer, 5% w/w solution in ethanol) can be added to 
either the glucose or oxygen sensor to act as a diffusion barrier and help to prevent 
biofouling.  
 
 
Figure 10.  Enzyme films used in the MAMP.  Glucose and lactate are measured 
indirectly through the reduction at + 0.6 V of hydrogen peroxide created by reaction with 
their respective oxidase enzymes, GOx and LOx.  Enzyme films are formed by hand 
casting a solution of the enzyme, bovine serum albumin, and glutaraldehyde onto the 
electrode surface.  A layer of Nafion can be added to the GOx film to act as a diffusion 
barrier and help prevent biofouling.    
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In an MAMP experiment to measure basal metabolic rates, cells are introduced 
into the MAMP, and data collection is begun.  Once the cells equilibrate for at least one 
hour, they are killed using alamethicin, a cell permeabilizing agent,36 to collect the sensor 
responses in the absence of cellular activity and calibrate the enzyme films with solutions 
of known glucose and lactate concentration.  Sodium fluoride was used in initial 
experiments as a means of metabolic inactivation.16  The production of lactate is 
prevented in the presence of sodium fluoride, an inhibitor of enolase, which converts 2-
phosphoglycerate to phosphoenolpyruvate.37  However, sodium fluoride does not 
completely inhibit glycolysis38 and has been shown to be an interferent in tests utilizing 
glucose oxidase.39  The media sold by Molecular Devices for use in the Cytosensor is low 
buffered (1 mM phosphate) and contains 11 mM glucose.31  In order to use a more 
physiologically relevant glucose concentration (5 mM)40 and calibrate the glucose sensor, 
a custom media was developed in conjunction with Mediatech, which is identical to the 
media sold by Molecular Devices but without glucose. 
MAMP data is reported as current (nA) with time; Figure 11 shows the response 
of a glucose oxidase sensor for a single stop-flow cycle with live and dead cells.  With 
the pump on, the media flows at a rate of 100 µL/min, and the current response is steady 
state.  When the pumps stop, the current decays as glucose is depleted from the media by 
the cells and also at the sensor.  When the pump restarts, the media is refreshed, and the 
current returns to its steady state value.  The current response of a given stop flow period, 
ip, is defined as the difference between the steady state current and the current at the end 
of the stop flow.  Data is then analyzed by subtracting the response with dead cells from  
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Figure 11.  Current response at glucose oxidase electrode for a single stop flow with live 
and dead cells.  The current is at a steady state with the pumps on (-10 to 0 s) and then 
decays when the pump is off (0 to 40 s).  Upon resumption of flow, the current returns to 
its steady state level. 
 
 
the response with live cells to obtain the current response due to cellular activity, Δip in 
Figure 11. 
The concentration in the chamber at the end of the stop flow is calculated from Δip 
using the calibration at the end of the experiment.  By accounting for the microfluidic 
volume, the number of cells present, and the length of the stop flow period, metabolic 
rates can be calculated in terms of mol cell-1 s-1.  Modeling efforts are underway to 
develop methods of analyzing the data over the entire stop flow period by modeling the 
stop flow period as a Cottrell step and through a mathematical model.  
The research presented in this dissertation is focused on improving the robustness 
of multianalyte microphysiometry as a tool in metabonomics.  A new multipotentiostat 
has been developed, with each chamber having three working electrodes and an 
individual reference and counter electrode.  This allows for the simultaneous collection of 
data from up to eight channels of the MAMP. Through the development of an insulin 
sensitive electrode and study of the metabolic responses of isolated murine islets, the 
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MAMP has been applied to new areas of research.  The MAMP has been utilized as a 
tool for investigating the signaling pathways that lead to the metabolic response measured 
when cells are exposed to a toxin.   
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CHAPTER III* 
 
DEVELOPMENT FOR A MULTICHAMBER MULTIPOTENTIOSTAT FOR 
MULITANALYTE MICROPHYSIOMETRY IN EIGHT ELECTROCHEMICAL 
CELLS SIMULTANEOUSLY 
 
Introduction 
One of the first electrochemical biosensors was the Clark electrode developed in 
1953 by Lealand C. Clark, to measure the level of dissolved oxygen in blood.41  In a 
Clark electrode, the sensor contains a gas permeable membrane through which oxygen, 
nitrogen, and carbon dioxide all diffuse.  However, only oxygen is reduced at the cathode 
through the following reaction (Eq. 1).42    
 (Eq. 1)  
The development of amperometric sensors has been linked to the need for blood 
glucose monitoring, which is employed by diabetics who comprise 5% of the world 
population.  No other bioassay is performed as frequently.43  Blood glucose monitoring 
accounts for approximately 85% of the biosensor market.44  The idea of a glucose enzyme 
electrode was first proposed by Clark and Lyons in 1962.45  This first sensor was a thin 
layer of glucose oxidase trapped over a Clark oxygen electrode.  Glucose oxidase reacts 
oxygen in the enzyme-catalyzed reaction shown in Equation 2.   
 (Eq. 2) 
The amount of oxygen consumed at the electrode could thus be linked to the 
concentration of glucose present. 
 
* Lima, E.A.; Snider, R.M.; Reiserer, R.S.; Wikswo, J.P.; Cliffel, D.E.  (to be submitted to Sensors and 
Actuators B) 
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In 1973, an amperometric sensor for direct oxidation of the hydrogen peroxide, 
Equation. 3,44 produced by the enzymatic reaction of glucose oxidase was developed by 
Guilbault and Lubrano.46   
 (Eq. 3) 
Today amperometric electrodes have been developed for a great number of 
biological molecules.  Electrochemical sensors have been widely used in the field of 
neuroscience due to the large number of electrochemically active neurotransmitters 
including catecholamine, indolamine, glutamate, lactate, ascorbate, nitric oxide, 
dopamine, acetylcholine, and choline.47,48   Electrodes have been able to be implanted into 
the brains of mice, allowing real time measurements of neurotransmitter release.49  Today 
electrochemical biosensors are being utilized in a number of fields including toxicology 
to provide high throughput electrochemistry through the use of interdigitated electrode 
arrays,50 instrumented well plates,51,52 and addressable electrode arrays.53 
 
Potentiostat Design 
All amperometric sensors are based upon the oxidation or reduction of an analyte 
and require a three-electrode potentiostat instrument that controls the working electrode, 
counter electrode and reference eletrode.33,54   A potentiostat is used to measure the 
current that passes between the working electrode and counter electrode, while holding 
the potential of the working electrode constant in relation to the reference electrode.33,42 
The term “potentiostat” was coined by A. Hickling, who developed the first instrument 
capable of automatic potential control.54-56  Hickling’s potentiostat spurred research into 
! 
H
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controlled potential methods, as it did not require continuous operator control of the 
applied potential.54,56   
A simple potentiostat based on a single operational amplifier serves as the basis 
for a Wenking potentiostat.  In the Wenking design, the working electrode is held at 
absolute ground, the desired applied potential is inverted into the input of the op-amp, 
and the counter connected to the output of the op-amp.  The current is measured in a 
series resistor coming out of the op-amp.   A key feature of this design is that there is no 
direct electronic feedback from the output of the op-amp to the inputs, making the 
amplifier an open-loop configuration, which is inherently prone to high frequency 
oscillations.    
Improvements on this most basic design include the use of an electrometer circuit 
to measure the current between the counter and the working electrodes.   This 
electrometer circuit holds the working electrode at virtual ground and replaces the series 
resistors of the Wenking potentiostats for current measurements.  Other typical 
improvements include a voltage follower circuit to invert the desired potential at the 
reference electrode, and a current buffer to allow the counter electrode to draw larger 
currents.33,54,56 
Development of more advanced potentiostat designs for a wide range of specific 
instrumental needs has flourished in both academic and commercial fields.  The design of 
advanced potentiostat instrumentation is based on the simple potentiostat circuit 
described above, but focuses on the specific improvements necessary for desired 
applications.   These specific improvements include faster time responses leading to 
faster scan rates, lower power consumption, field portability, bi- and multi-potentiostats, 
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and electrically isolated circuitry.   Faster time responses involving positive feedback 
compensation have enabled the development of fast-scan cyclic voltammetry 
measurements with scan rates over a megavolt per second.57  Lower power consumption 
enables the development of long-lived battery powered potentiostats at low-cost for 
miniaturization.58  Combination of low power, miniaturization, and integrated electronics 
enabled field portable designs for numerous hand-held biosensor applications.59-64   
Electrically isolated circuitry enables potentiostats to be combined with other electronic 
instrumentation such as on-chip capillary electrophoresis,65 and can be accomplished 
using opto-couplers.66  Simultaneous measurements can be performed in multiple 
electrochemical cells, each comprised of an individual set of working, counter, and 
references electrodes, forming an array of single analyte potentiostats.67  Scribner and 
Associates have developed a commercial multichannel potentiostat that has 100 working 
electrodes all at the same potential, each with its own electrometer circuitry, and a single 
counter and reference electrode, and a 64 working electrode system was described in the 
literature.68   
In contrast, the design of two working electrodes with independent potential 
control in a single electrochemical cell leads to conventional bipotentiostats.33  Expanding 
the number of working electrodes per electrochemical cell has led to multipotentiostats 
like a quadpotentiostat69 and the commercial CH Instruments 1030 which controls eight 
separate working electrode potentials with a single counter and reference. 
In order to measure multiple analytes in multiple electrochemical cells 
simultaneously, we have created a multichamber multipotentiostat.   This multichamber 
multipotentiostat consists of an array of 4 or 8 multipotentiostats operating 
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simultaneously, similar to the array of single potentiostats by Popovtzer.67  Each of these 
multipotentiostats has three working electrodes, two of which shared the same applied 
potential, as in the Scribner potentiostat design,68 and one of which has a separate 
working electrode potential as in a conventional adder multipotentiostat like the CHI 
1030.  This multichamber multipotentiostat enables us to monitor multiple analytes in 
different fluidic chambers simultaneously.  This instrument could be used for 
instrumenting conventional well-plates with multiple electrochemical sensors, but our 
specific application has been to develop multianalyte microphysiometry in microfluidic 
chambers. 
Conventional 4 or 8 chamber microphysiometry was commercialized as the 
Cytosensor by Molecular Devices and measured pH to obtain the extracellular 
acidification rates (ECAR) using a light addressable potentiometric sensor (LAPS), 
where the ECAR are correlated to changes in cellular metabolism.  Multianalyte 
microphysiometer (MAMP) expanded upon the Cytosensor® microphysiometer with the 
addition of amperometric electrodes for monitoring glucose, lactate and oxygen.  Using 
our multichamber multipotentiostats, the MAMP can be used to measure the four-analyte 
metabolic response of cells in either four or eight microfluidic chambers simultaneously.  
The reference electrode is downstream from the microfluidic chamber and is shared with 
the potentiometric measurement of the LAPS.   The amperometric measurements utilize a 
modified sensor head with three working electrodes and a counter electrode in each 
chamber.   Thus each microfluidic chamber is a discrete electrochemical cell with its own 
reference and counter electrodes and three working electrodes.16,18,19 
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Initial MAMP experiments were developed utilizing a CH Instruments 1030 
multipotentiostat.16,18,19  This instrument is capable of measuring up to eight working 
electrodes simultaneously; however, it is designed for all eight working electrodes to be 
used in a single electrochemical cell.  For this reason, only a single chamber of the 
MAMP could be utilized at any given time.  Also, it is not feasible to run multiple 1030 
multipotentiostats off of a single computer.  Thus, there was a need to develop a 
multichamber multipotentiostat capable of recording the amperometric response in eight 
electrochemical cells of three working electrodes each simultaneously.   To be best suited 
for the MAMP, the multipotentiostat must be capable of reliable measurement at a low 
frequency to help prevent cross talk with the high frequency LAPS sensor (10 kHz).30    
 
Experimental 
Assembly 
The multichamber multipotentiostat designed for use with the MAMP is a 
combination of features of previous multipotentiostat designs with two working 
electrodes being held at the same potential (CF1 and CF2), and a third at a separate 
potential (CF3).  A schematic of this design type is shown in Figure 12.33  In this 
potentiostat, the current outputs for each working electrode are read using an electrometer 
circuit (current followers: CF1, CF2, and CF3).  In the design for our multipotentiostat, 
the feedback resistance for each electrometer is digitally selected with a multiplexer 
based on the sensitivity setting in the LabVIEW software from a set of four resistors as 
shown in Figure 13.   The reference electrode is directly connected to F1, a voltage 
follower that fixes the reference potential at the negative of the input working electrode 
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potential while providing a high impedance at the reference electrode.  The potential 
control amplifier, PC, is the heart of the potentiostat (the Wenking single op-amp 
equivalent) and does not have a feedback loop except for some small capacitors that are 
used to reduce the problems with tripping into oscillations.  The second potential control 
circuitry is shown in the top right of Figure 12, where the first inverting amplifier, I2, 
provides the inverted second potential to a zero shift adder amplifier, Z2, that results in 
an output potential that is the difference between the second applied potential and the first 
applied potential.  This potential difference, Δe, is then used as the positive input 
potential for the electrometer for the separate potential working electrode, CF3.  The 
potential output of CF3 would normally need to be measured differentially; however, we 
use an instrumentational amplifier to subtract Δe after CF3 and are able to measure the 
differential output voltage generated as a non-referenced single ended input to the DAQ 
card. 
Multipotentiostat modules were designed and built by Ron Reiserer and Eduardo 
Lima.  Each multipotentiostat module performs the functions shown in Figure 12 and is 
used to measure one electrochemical cell chamber.  The multipotentiostat modules are 
stacked into an array of 4 or 8 modules that are each connected in a backplane and 
comprise the multichamber multipotentiostat.  A detailed description of the schematics 
and assembly of the multipotentiostat modules, written by Eduardo Lima, who built the 
potentiostat modules and wrote software for their calibration, is given in Appendix A.  
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Figure 12.  Adder bipotentiostat with three working electrodes [Adapted from Bard]33 
 
 
Figure 13.  Current follower with four switchable resistors [Adapted from Bard]33 
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Computer control 
The MAMP system was controlled as described by Eklund with a Macintosh 
computer whose Cytosoft™ program controlled the pumps and temperature controls of 
the MAMP.16  A separate Pentium IV personal computer was used to control the 
multichannel multipotentiostat via National Instruments data acquisition (DAQ) cards 
and custom designed LabVIEW software.  For four chamber MAMPs and 
multipotentiostats, either the PCI-6036E or PCI-6221 DAQ card was used, and in eight-
channel systems PCI-6229 was used. Standard National Instruments shielded 68-pin 
cables (SH68-68-EP and SHC68-68-EPM) connected the DAQ cards to the configuration 
card of the potentiostat. 
 
Software 
LabVIEW software for the calibration of the multipotentiostat modules was 
written by Eduardo Lima.  The front panel of this software is shown in Figure 14A, and a 
section of the block diagram which controls data acquisition is shown in Figure 14B.   
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Figure 14. LabVIEW program written for calibration of multichannel multipotentiostats.  
A) Front Panel B) Block diagram showing the portion of the program that deals with data 
collection 
 A 
B 
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LabVIEW software was also written for the multipotentiostat for multichamber 
amperometry experiments.  A schematic flow diagram of the program is shown in Figure 
15.  Figure 16 shows the front panel of the program showing the user inputs of 
sensitivity, electrode potential, run time, sample rate, and sample name.  The segment of 
the block diagram dealing with data collection and display is shown in Figure 17. 
 
 
Figure 15.  Flow diagram of data collection software for the multipotentiostat 
 
Initialization
Set up communication between DAQ 
board and multipotentiostat
Select sensitivity, electrode potentials, 
quiet time, and run time
Connect to Instrument
Connect relays and apply potential
Quiet Time
Data Collection
Read value from DAQ board, convert to 
current using calibration factors, and graph
This section runs until the run time is complete 
or the user presses stop
Complete Experiment
Save data to file and reset 
circuit board and instrument
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Figure 16.  User interface of the LabVIEW program written for the multipotentiostat for 
use with the MAMP 
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Figure 17.  Portion of the block diagram of multipotentiostat software for the MAMP 
dealing with data collection, graphing, and saving to file 
 
 
 
Calibration of the Multipotentiostat Modules 
In order to calibrate each module of the multipotentiostat, a “dummy cell” 
comprised of four resistors, as shown in Figure 18, is used. The offset voltage of the 
DAQ card in applying a potential to the working electrodes must determined. As this 
offset potential is applied to each individual multipotentiostat module slot, an average 
offset is found by measurement from each card. A single offset value was determined for 
working electrodes one and two, as the same potential is applied at both electrodes.  A 
separate offset value is determined for working electrode three.    
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Figure 18.  “Dummy cell” used in calibration of multipotentiostats 
 
 
 
The determination of the specific feedback resistance, Rf, in each circuit is 
required to accurately convert voltages on the DAQ card back into amperometric 
currents.  Based upon the sensitivity selected, one of four resistors, with value Rf, is 
connected to the current follower circuit, shown as R1 through R4 in Figure 13, with       
Vo = -IRf, so that Vo remains between + 10 V.  By connecting a resistor of known 
resistance Ri of the dummy cell to the input and applying a known potential Vi, the value 
of Rf can be determined using the relationship, Vo = -(Rf/Ri)*Vi.  The offset of the DAQ 
card response is included in the value of Rf calculated here.  The value of Rf is then used 
to convert the voltage read on the DAQ card to the current measured at the working 
electrode. 
 
Timing Studies 
Tests were performed with the multipotentiostat and the MAMP to determine the 
reliability and high frequency noise using a sample rate of 1 Hz typical of MAMP 
experiments. Timing studies at higher frequencies were performed using dummy cells to 
allow testing without interfering with the LAPS of the MAMP.  The dummy cells were 
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connected, and the amperometric response and noise backgrounds were measured at 
varying sample rates. 
 
Amperometric Testing of the Multipotentiostat with the MAMP 
Tests were performed with the multipotentiostat and the MAMP to measure the 
amperometric response and noise of the working electrodes of modified sensor heads, 
which are shown in Figure 9 in Chapter II. The sensors in the MAMP were tested with 
and without enzyme films, and with enzyme films in the presence of pheochromacytoma 
cells (~5 x 105 per insert, PC-12, CRL-1721 from the American Type Culture Collection 
(ATCC)). All MAMP protocols for cell cup and enzyme film preparation followed those 
given in Chapter II.  Working electrode one (WE1) was coated with a glucose oxidase 
enzyme film, and working electrode two (WE2) was coated with a lactate oxidase 
enzyme film. WE1 and WE2 are 0.5 mm platinum electrodes.  The 127 µm platinum 
electrode was working electrode 3 (WE3) and was left bare.   Films were hand cast onto 
the surface of the platinum electrodes on the modified sensor heads and allowed to dry 
for 45 minutes before being used in the MAMP.  
In these tests, working electrodes one and two were held at +0.6 V vs. the 
Ag/AgCl (2M KCl) reference of the MAMP.  Working electrode three was held at -0.45 
V vs. the Ag/AgCl (2M KCl) reference of the MAMP.   All experiments were performed 
using 5 mM glucose modified RPMI 1640 media. In all experiments the sensors were 
calibrated with modified RMPI media with no glucose and no lactate, with 0.05 mM 
lactate and 1 mM glucose, with 0.1 mM lactate and 3 mM glucose, with 0.2 mM lactate 
and 5 mM glucose.  
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In the test of sensors without films and no cells, the sensors were placed into 
Corning Costar® Transwell® cup assemblies without cells, perifused with media, and the 
current response recorded.  In the test with enzyme films but no cells, the sensors were 
placed into Corning Costar® Transwell® cup assemblies without cells; the current 
response was recorded as the chamber was perifused with media and the enzyme films on 
the sensors were calibrated. In the test with enzyme films and PC-12 cells, the sensors 
were placed into Corning Costar® Transwell® cup assemblies containing the cells and the 
current response recorded as the chamber was perifused with 5 mM glucose modified 
RPMI 1640 media for 45 minutes. The media was then changed to modified RPMI 1640 
media containing 5 mM glucose and 101 µΜ alamethicin. Once the cells were dead, the 
enzyme films of the sensors were calibrated. 
 
Results and Discussion 
Calibration 
The offsets for each DAQ card and calibration factors for the instrument were 
determined. The offset values were found to be less than 60 mV for working electrodes 
one and two and less than 20 mV for working electrode three.  These were then corrected 
for in the potential applied in the LabVIEW program.  The calibration factors for the 
feedback resistances necessary for converting the measured voltage to a current were 
found to be within 10 % of the defined sensitivity, as expected given the tolerances of the 
resistors used.   The Rf values determined for each module of a 4 chamber 
multipotentiostat are given in Table 1.   
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Table 1.  Calibration values determined for a 4 chamber multipotentiostat 
 
 
 
 
Timing Studies 
In a five hour thirty-five minute experiment in the MAMP with sample rate of 1 
Hz, the average error in timing over the course of the experiment was 1.4 ms. For use in 
other experimental setups where there is not the issue of interference with the 10 kHz 
LAPS of the MAMP, sampling as fast as 10 Hz is possible with time steps of 0.100 + 
0.008 s. 
 
Testing of Sensors in the MAMP 
The amperometric response of a modified sensor head without films in the 
absence of cells is shown in Figure 19. The current response of working electrode one 
and two is very similar, which indicates that the electrodes of the modified sensor head 
are of similar area.   
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Figure 19.  Current response of bare modified sensor head without cells present in 
modified RPMI 1640 media with 5 mM glucose 
 
 
 
The amperometric response of a modified sensor head with enzyme films in the 
absence of cells is shown in Figure 19.  When cells are absent and the chamber contains 
modified RPMI 1640 media containing 5 mM glucose, there is no stop flow signal on the 
lactate oxidase electrode (WE 2) and the magnitude of the oxidation current at the 
glucose oxidase electrode (WE 1) increases during stop flow.  There is a linear 
calibration of both the glucose oxidase and lactate oxidase electrodes.  The signals at the 
bare platinum oxygen electrode (WE 3) remain constant through out the experiment. 
 
 
Figure 20.  Current response at modified sensor head with WE1 coated with glucose 
oxidase, WE2 coated with lactate oxidase, and WE3 bare without cells present.  
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The amperometric response of a modified sensor head with enzyme films in the 
presence of cells is shown in Figure 21. In the presence of cells with media containing 5 
mM glucose before they are treated with alamethicin, the magnitude of the oxidation 
current at the lactate oxidase electrode increases during the stop flow and the magnitudes 
of the currents at the glucose oxidase electrode and bare platinum oxygen electrode 
decrease during the stop flow.  These results are consistent with lactate being produced 
and oxygen and glucose being consumed by the cells.  At the end of treatment with 
 
 
Figure 21.  Current response at modified sensor head with WE1 coated with glucose 
oxidase, WE2 coated with lactate oxidase, and WE3 bare with 5 x 105 PC-12 
pheochromacytoma cells.  
 
 
 
current at the lactate oxidase electrode increases during the stop flow and the magnitudes 
of the currents at the glucose oxidase electrode and bare platinum oxygen electrode 
decrease during the stop flow.  These results are consistent with lactate being produced 
and oxygen and glucose being consumed by the cells.  At the end of treatment with 
alamethicin, when the cells have died, there is no longer a significant change in the 
current at the lactate oxidase electrode, and the decreases in the magnitude of the current 
at the glucose oxidase electrode and at the bare platinum oxygen electrode are less during 
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stop flow.  These results are consistent with there being less glucose and oxygen 
consumed during the stop flow.  This multichamber multipotentiostat has since been used 
in studies of cancer metabolism,70,71 islet physiology,72,73 and studies of the effects of 
toxins on cellular metabolism.17  
  
Conclusions 
We have developed a multipotentiostat capable of simultaneously measuring 
amperometric current response of three working electrodes in up to eight electrochemical 
cell chambers at a controlled bandwidth.  This multipotentiostat works with sensitivities 
of 1, 10, 100, or 1000 nA/V, depending on the feedback resistor selected.  The timing of 
the sample rate at 1 Hz has a low standard deviation of 1.4 ms over the course of a five 
and a half hour experiment, and data can be collected for as long as ten hours.  Sampling 
frequencies as high as 10 Hz can also be used, when the LAPS is off, thereby eliminating 
the high frequency noise from crosstalk.    
This multipotentiostat is applicable to any system requiring amperometric 
measurements in multiple electrochemical cells simultaneously, such as in an 
instrumented well plate.  The only limitation is that the current design is limited to the 
application of two potentials; however, this is not a significant issue so long as two of the 
analytes have similar reduction or oxidation potentials. 
The use of this multipotentiostat increases the number of MAMP chambers that 
could be measured simultaneously from 1 to 8, allowing for simultaneous testing of 
multiple cell types or exposures or simply allowing replicate experiments to be run 
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simultaneously. Currently efforts are underway to integrate new instrumentation modules 
for potentiometric measurements of pH and Ca2+, such as in the work of Yicong.20,74 
 
Acknowledgments 
I would like to acknowledge Eduardo Lima, a postdoctoral research associate, and 
Ron Reiserer, laboratory manager of the Vanderbilt Institute for Integrative Biosystems 
Research and Education, who built the multipotentiostat modules and performed 
electronics testing.  Dr. Eduardo Lima also wrote software that was used to calibrate the 
DAQ cards used with the multipotentiostat.  
39 
CHAPTER IV 
 
STUDIES OF ISLET METABOLISM IN THE MAMP 
 
Introduction 
The detection of insulin is important in the study of the metabolic function of 
islets, the cells that produce insulin.  These cells, their function, dysfunction, and 
destruction, play a critical role in diabetes.  Diabetes mellitus affects two hundred million 
people worldwide, six percent of the world's population.75  Type I diabetes mellitus 
(T1DM) accounts for up to 10% of diabetes cases worldwide and occurs when the 
immune system attacks the insulin-producing cells of the pancreas.76  
The human pancreas is comprised of exocrine tissue that excretes digestive 
enzymes through ducts and endocrine tissue that releases hormones into the bloodstream.  
Endocrine function is performed by the islets of Langerhans, clusters of cells scattered 
throughout the exocrine tissue of the pancreas,77 as shown in Figure 22.78  Islets vary in 
size from less than 40 µm up to 400 µm in diameter as the number of cells varies from a 
few cells to 5,000 cells.79 
 
 
Figure 22.  Pancreatic islet78 
 
* Snider, R. M.; Ciobanu, M.; Rue, A. E.; Cliffel, D. E. Anal Chim Acta 2008, 609, 44-52. 
Ciobanu, M.; Snider, R.M.; Rue, A.E.; Chen, Z.: Powers, A.C.; Cliffel, D.E.  (for submission to Anal. Chem.) 
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Islets are comprised of four main cell types: insulin-producing β cells, glucagon-
producing α cells, somatostatin-producing δ cells, and pancreatic polypeptide-producing 
PP cells.77 Human islets are normally comprised of approximately 54% β cells,80 which  
are spread throughout the islet.  Murine islets contain 85% β cells, which form the core of 
the islet.81  Insulin secretion by β cells can be stimulated by glucose, as well as other 
molecules such as amino acids, fats, and horomes.82 Glucose stimulated insulin secretion 
is described as biphasic, with an initial peak of concentration followed by increased 
release to reach a plateau.83 A key event in glucose sensing is believed to be the 
phosphorylation of glucose by glucokinase (GK).84  Insulin release can also be triggered 
by elevated levels of potassium and other nutrients.85-87 
Insulin is synthesized within β cells in the form of pro-insulin, a single 
polypeptide chain containing the A and B chains and the C peptide linking region.  Prior 
to being secreted, insulin is converted within the secretory granule from pro-insulin to 
insulin by removal of the C peptide.79 As shown in Figure 23,88 human insulin has a 
molecular weight of approximately 9 kDa and is comprised of 51 amino acids in two 
polypeptide chains with the A chain containing 21 amino acids.77 The two strands are 
linked through two disulfide bonds with an intrastrand disulfide bond on the A chain.77,89  
 
 
Figure 23.  Human insulin showing the two interstrand and one intrastrand disulfide 
linkages88 
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The current state of the art treatment for T1DM is based upon delivery of insulin 
using pumps to stabilize the levels of glycosylated hemoglobin.  While this treatment is 
lifesaving, it is unable to completely prevent the development of medical complications 
of the eyes, kidneys, nerves, and blood vessels.90  In some patients, even with this 
treatment can cause severe hypoglycemia, leading to potentially life-threatening 
outcomes.91  For these patients, as well as those who have undergone a kidney transplant 
and thus will be on life-long anti-rejection therapy, the transplant of insulin producing 
tissue, either whole pancreas or islets is a possible treatment.91  In 1993, the diabetes 
control and complications trial set forth a strong rationale for pancreas transplant;92 
however, whole-organ pancreas transplant has significant risk of increased mortality.91   
Early human islet transplantations were relatively unsuccessful with fewer than 
12% of patients receiving islet allografts remaining insulin independent for more than a 
year, i.e. not requiring insulin injections.90 In 2000, Shapiro reported successful islet 
transplantation for seven patients that resulted in insulin independence for all patients for 
an average of 11.9 months.  A key factor in the reported success of this study, which 
came to be known as the Edmonton protocol, was the avoidance of corticosteroids in the 
immunosuppressive treatment of patients, following transplant.93 Further studies have 
confirmed one-year insulin independence rates of 80% and three year islet graft function 
rates of approximately 90%, based on detection of C-peptide from the conversion of 
proinsulin to insulin.75 A five year follow up with patients from the 2000 study by 
Shapiro showed that while 80% of the patients showed graft function only 10% remained 
insulin independent.94  This unexpected decrease in graft function, along with the 
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withdrawal of the enzyme used in pancreas digestion by Roche in 2007, has lead to 
decreased expectations of islet transplantation as a T1DM cure.91 
The steps involved in pancreatic islet transplant are shown in Figure 24.92  First, 
the pancreas is harvested from a donor and subjected to collagenase digestion to separate 
islets from exocrine tissue.  The pancreatic islets are then purified using density gradient 
centrifugation.  Next, purified islets are injected into the liver of the recipient through the 
portal vein.  As shown in Figure 24, islets become trapped within the sinusoids of the 
liver, where they perform their exocrine function.92  
 
 
Figure 24.  Procedure used in allogenic islet transplatation92 
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Since the 2000 study by Shapiro, there have been many advances in islet 
transplantation, particularly improvements in isolation procedures.75 However, the 
standard characteristic in the evaluation of the health and function of isolated islets prior 
to transplantation is still the rate of insulin release, as determined by standard static or 
perifusion experiments.95  Even in the most experienced isolation centers, more than 50% 
of islet mass can be lost during pancreatic digestion, purification and culture.91  
Additionally, the long term use of immunosuppressant even with improved protocols is 
associated with toxicity to islets.78  In order to address these issues, further in vitro study 
of the effect of digestion procedures and immunosuppressants on islet metabolism is 
warranted.  
In a typical standard static test, two samples of 5 or 10 islets are incubated for a 
period of time, typically one to two hours, one sample in media containing a low 
concentration of glucose (2.8-3.3 mM) and the other sample in media with a high 
concentration of glucose (16.7-20 mM).  The amount of insulin in the media is 
determined, and the stimulation index is calculated as the ratio of the insulin content in 
the high glucose media to the insulin content of the low glucose media.96-98  The 
stimulation index is used to quantify the insulin secreting capability of the islets; this 
measure is used in the analysis of islets for human transplants.93  In perifusion 
experiments, islets are immobilized in a fluid path, such as between glass frits in a tube, 
and media is flown past.  Typically, the islets equilibrate in low glucose media (~3 mM) 
for approximately 30 minutes to one hour, and then the glucose concentration is increased 
(~17 mM).  Samples of the media outflow are collected throughout the experiment, every 
one to two minutes, and the insulin content is then determined to obtain a rate of insulin 
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release.  The number of islets used in perifusion experiments varies from 5 to as many as 
50.99-103  In perifusion experiments, the concentration vs. time profile of secreted insulin 
can be compared to the expected glucose stimulated insulin response for healthy 
islets.83,104 Both of these techniques require ex situ analysis of insulin content from 
collected samples, and as these methods necessitate testing of sample fractions, the true 
dynamic insulin release profile is not observed because time averaging occurs.  Assay 
methods for the quantitative analysis of insulin in these samples include enzyme linked 
immunosorbent assay, radioimmunoassay, and chromatography.  While these assays can 
have very low detection limits, these methods can be time consuming and require the 
labeling of insulin with either fluorescent tags or radioisotopes.105-107 
Electrochemistry and fluorescence have also been used to quantify islet secretion 
with time resolution that reaches real-time in some cases; however, these studies 
primarily have involved detecting zinc, calcium or other molecules such as 5-
hydroxytryptamine that play a role in insulin secretion.108-112 Maghasi et al.108 detected 
secretion from β cells electrochemically through anodic stripping voltammetry of zinc at 
a bismuth-coated electrode.  This study proposed that the amount of zinc detected 
correlated to the amount of insulin secreted since insulin is stored primarily in crystalline 
form with encapsulated zinc ions. However, this detection method required 
preconcentration and ex situ analysis of the β cell culture supernatant.108 Kennedy and 
coworkers have been able to study insulin secretion by single islets in a microfluidic 
device through electrophoresis-based immunoassay of insulin111 and also through 
fluorescence spectroscopy of zinc and intracellular calcium.110  While these techniques 
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have very low detection limits, they are unable to measure unlabeled native insulin 
directly. 
Direct electrochemical detection of insulin is attractive as it can provide 
sensitivity and also reduced analysis times to enable continuous real-time measurements 
compared to the above methodologies.  One of the first chemically modified electrodes 
developed to measure the oxidation of insulin was a ruthenium dioxide/cyanoruthenate 
film on a glassy carbon fiber electrode;113 however this electrode operated at pH 2, 
making it impractical for physiological measurements.  A ruthenium 
dioxide/cyanoruthenate film on a carbon fiber microelectrode was later utilized at pH 7.4 
to monitor chemical secretion by single β cells in response to stimulation with glucose, 
tolbutamide, and potassium.114  Redox mediators and electrocatalysts such as ruthenium 
oxide,115 ruthenium metallodendrimer,116 and iridium oxide117 layers have been shown to 
promote the oxidation of insulin at physiological pH and have been used in amperometric 
detection and quantization of insulin.  However, iridium oxide sensors have the 
disadvantages of pH sensitivity resulting from the proton mediated nature of electron 
transfer and also the slow nature of proton transport within the film that delays the 
electrode response;118 ruthenium oxide and ruthenium metallodendrimer films have 
mixed redox states leading to complex electron transfer kinetics, with the electrochemical 
behavior of ruthenium oxide varying between crystal faces.119 While these sensors have 
been used to detect insulin electrochemically, they have limited stability of their mixed 
redox state surface films leading to loss of insulin sensitivity. 
Because of the difficulties associated with the above chemically modified 
electrodes, multiwalled carbon nanotubes (MWCNTs) are an attractive possibility as an 
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electrocatalyst for the oxidation of insulin.  MWCNTs are long, multi-walled, thin 
cylinders of carbon that can be described as several two-dimensional graphite sheets 
rolled into a tube.120  Figure 25 shows a transmission electron micrograph of a MWCNT 
containing a concentric nested array of nine single walled nanotubes.120   
 
 
Figure 25.  Transmission electron micrograph of a single MWCNT120 
 
 
Recent studies have shown the ability of MWCNTs to promote electron transfer 
reactions of both important biomolecules53,121 and redox centers embedded deep within 
proteins.122,123 This electrocatalytic property, as well as the chemical stability and high 
mechanical strength of MWCNTs, has rendered them an appealing material for use in 
biosensors.124 Also, MWCNT-modified electrodes have been shown to reduce surface 
fouling effects, like those seen in NADH oxidation at highly ordered pyrolytic graphite 
electrodes.125  
The direct oxidation of insulin with high sensitivity in physiological pH using a 
MWCNT modified glassy carbon electrode (GCE) cast from a suspension in N,N-
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dimethylformamide (DMF) was reported by Wang and Musameh.126 No cross-linking 
agent or polymer was used in the preparation of this film.  Because the film was produced 
upon the evaporation of DMF, there was little control of film morphology leading to 
agglomeration of the MWCNTs.  Recent improvements by Wang and co-workers include 
a combination carbon nanotube/ruthenium oxide electrode.127  Wu et al. reported that the 
stability of MWCNT films for the detection of small biomolecules is improved by 
addition of a fatty acid such as dihexadecyl phosphate to an aqueous suspension of 
MWCNTs.128  Gorski et al. recently explored the use of a chitosan MWCNT composite 
film for insulin oxidation.129 The addition of the polysaccharide chitosan was seen to 
facilitate the preparation of films for electrochemical sensors, but these sensors were not 
coupled to microfluidic analysis nor used for direct insulin measurements on islets.  The 
preparation of the chitosan-based film includes the use of an acid solution at 80–90 ºC 
and results in a film up to 10 µm thick.129 In our microphysiometer setup, a thick film 
may prove an impediment in the microfluidic thin layer cell where the volume of the 
microfluidic chamber is 3 µL.  The use of a small molecule, such as dihydropyran (DHP), 
as a stabilizing agent for the MWCNT film should result in a simpler preparation as DHP 
is simply added to the aqueous suspension.  DHP is a vinyl ether that has been shown to 
self-polymerize,130 and therefore has the ability to form a thinner stabilizing network for 
adhering the MWCNTs to the glassy carbon surface.   
An electrochemical insulin sensor would be ideally suited for use in the 
physiological detection of insulin in a microfluidic device, such as the MAMP, which is 
described in more detail in Chapter II.  In the MAMP, as in all microfluidic devices, the 
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film electrodes must be able to withstand the shear forces generated in the detection 
chamber. 
In this chapter, we present an insulin sensor for electrochemical detection in a 
microfluidic device based on direct oxidation at a MWCNT/DHP composite film at 
physiological pH.  Compared to sensors in literature, our sensor has improved surface 
coverage and adherence to the electrode surface.  We have successfully adapted this 
sensor for the microfluidic chamber of the MAMP and used it to record the response of 
isolated murine islets to glucose stimulation, as well as nutrient stimulation.  
 
Experimental  
Chemicals 
All materials were used as obtained unless otherwise noted.  Insulin (from bovine 
pancreas, 27 USP units/mg), and dihexadecyl phosphate were purchased from Sigma.  
The insulin content appeared to vary as much as 20% between commercial lots.  3,4-
Dihydro-2H-pyran (DHP), Tween-80, and DMF were purchased from Acros.  Cell-Tak 
cell and tissue adhesive was purchased from BD Biosciences.  Glassy carbon rods (1 mm 
diameter) were obtained from Structure Probe, Inc. (West Chester, PA).  Platinum rod (2 
mm) was purchased from VWR.  All microphysiometer consumables were purchased 
from Molecular Devices (Sunnyvale, CA).  
Insulin solutions were prepared from a stock of 10 mg/mL solution of insulin in 
19.6 mM hydrochloric acid containing 0.02% v/v Tween-80.  Dilutions were then made 
in 50 mM phosphate buffer (pH 7.4, 0.02% v/v Tween-80) immediately before use in 
experiments.  Male FVB (Friend leukemia virus B) mice were made available by the Islet 
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Isolation Core of the Vanderbilt Diabetes Research and Training Center.  FVB mice have 
been used previously as control models for basal levels in a number of studies of the 
effect of gene modification on insulin secretion.131-133  Islets were isolated from these mice 
by Dr. Zhongyi Chen of the Islet Isolation Core of the Vanderbilt Diabetes Research 
Training Center  as described by Brissova et al.134  The islets were cultured overnight in 
RPMI with 10% fetal bovine serum and 11 mM glucose.  Upon receipt the islets were 
stored in an incubator at 37 °C and 5% CO2 until use. 
MWCNTs were obtained as a gift from Dr. William Hofmeister and were 
manufactured as a byproduct of diamond deposition by microwave assisted chemical 
vapor deposition using an iron catalyst.  An Astex Large Area Diamond Deposition 
System with a 5 kW microwave source was used.  Nanotubes were purified through 
treatment with nitric acid, following the method of Dujardin et al.,135 to remove the 
remaining catalyst and aggregates.  Following purification, the nanotubes were stored in a 
desiccator. 
  
Apparatus 
All electrochemical measurements, with the exception of amperometric tests in 
the MAMP, were conducted using a CHI 660a potentiostat from CH Instruments (Austin, 
TX).  The electrochemical cell was used in a three electrode configuration with 3 mm 
GCE working electrode CHI104 (CH Instruments Austin, TX), Ag/AgCl (2 M KCl) 
reference electrode CHI 111 (CH Instruments Austin, TX), and platinum mesh counter 
electrode in all experiments but those in the MAMP.  In the MAMP, the 2 mm platinum 
disk on the modified sensor head  (Figure 26) was used as the counter and the 1 mm 
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glassy carbon electrode was used as a working electrode, while the reference electrode 
(Ag/AgCl, 2 M KCl) was downstream from the microfluidic chamber, as is typical in the 
Cytosensor®.  For amperometric tests in the MAMP, a four channel microphysiometer 
and Cytosoft® program (Molecular Devices) were used to control pump cycles.  The 
multipotentiostat described in Chapter III was used to measure the current response in 
MAMP experiments.   
 
Sensor Head Construction 
 For insulin determination in the MAMP, a sensor head was constructed with a 1 
mm GCE, a 0.5 mm platinum working electrode, a 127 µm platinum working electrode, 
and a 2 mm platinum counter electrode, as described in Chapter II.  The GCE was 
connected to platinum wire with silver epoxy to allow electrical connection.  All 
electrodes were sealed with Hysol® Epoxi-Patch and polished until flush with the surface.  
The schematic of the modified sensor head can be seen in Figure 26.  
 
 
 
Figure 26.  Modified sensor head with 1 mm GCE (A), 2 mm (B), 0.5 mm (C), and 127 
µm (D) platinum electrodes 
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Modified Electrodes for the Detection of Insulin 
All films were formed by drop casting the suspension on to the electrode surface, 
with 20 µL used for a 3 mm GCE and 3 µL for a 1 mm sensor head GCE.   
MWCNTs cast from DMF: A 10 mg/mL suspension of carbon nanotubes in DMF 
was sonicated for one hour.126  
MWCNT/dihexadecyl phosphate: A 10 mg/mL suspension of MWCNT in water 
was prepared with a 1:1 mass ratio of MWCNT:dihexadecyl phosphate.  The suspension 
was sonicated for one hour.128  
MWCNT/DHP: A 10 mg/mL suspension of MWCNT in water was prepared with 
a 1:1 mass ratio of MWCNT:DHP.  This suspension was sonicated for fifteen minutes. 
 
Testing of Films for Insulin Sensitivity  
Cyclic voltammograms (CVs) were obtained for each electrode film on the 3 mm 
GCE and 1 mm GCE of the modified sensor head in 50 mM phosphate buffer (pH 7.4, 
0.02% v/v Tween-80) with and without insulin, from 0 to 1 V at a scan rate of 50 mV/s.   
The MWCNT/DHP film on the 3 mm GCE was also calibrated outside of the MAMP in a 
batch test.  After ~1 hour of electrode conditioning at +0.88 V vs. Ag/AgCl (2 M KCl) in 
50 mM phosphate buffer (pH 7.4, 0.02% v/v Tween-80), aliquots of buffer and insulin 
were injected to give concentrations of 0, 1.97 x 10-7, 3.94 x 10-7, 6.87 x 10-7, and 9.79 x 
10-7 M insulin. The resulting data was filtered using a LabVIEW program with a Fourier 
transform low pass filter to remove the electromagnetic stirring noise.   
To test the suitability of these films for use in the MAMP, the 1 mm sensor head 
GCE was coated with one of the three film types and then placed in the MAMP for 4.5 
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hours under stop flow conditions with a cycle of 180 s with a flow rate of 20 µL/min for 
140 s and a 40 s stop flow period.  The condition of the films was observed using an 
optical microscope before and after testing.  Linear sweep voltammetry (LSV) in 
solutions of buffer and insulin was performed with a scan rate of 50 mV/s in the 
microphysiometer for films on the sensor head GCE at a constant flow rate of 20 µL/min.  
The MWCNT/DHP composite film was then calibrated amperometrically on the 
modified sensor head in the MAMP with ~1 hour of electrode conditioning following the 
same method used in the batch test of the film on the 3 mm GCE, with concentrations of 
0, 1.001 x 10-6, 5.002 x 10-6, 1.001 x 10-5, 2.501 x 10-5 M insulin.    
 
Testing of Islets in the MAMP 
The polycarbonate membranes of the Cytosensor® capsule cups were coated with 
Cell-Tak™, a combination of proteins from mussels.  The cups were dried at 37 °C, 
rinsed with water, and dried again.  Approximately 75-125 islets were hand picked from 
the culture media using a manual pipette, rinsed three times with 1 mM phosphate buffer 
with 100 mM NaCl (pH 7.0), and then placed onto the Cell-Tak™.  The islets were then 
coated with 5 µL of agarose following a well established protocol for the use of non-
adherent cells in the Cytosensor®.21,136,137  A spacer and insert were placed inside the cup.  
Hank’s balanced salt solution (HBSS)138 with 2.8 mM glucose was pipetted inside.  For 
all islet experiments, the glassy carbon electrode was coated with 3 µL of 10 mg/mL 
suspension of MWCNT in water with a 1:1 mass ratio of MWCNT:DHP.  The 0.5 mm 
platinum electrode was coated with a solution of lactate oxidase and bovine serum 
albumin in pH 7 phosphate buffer.  Both films were allowed to dry for 45 minutes.  These 
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two electrodes were held at a potential of +0.88 V vs. Ag/AgCl (2 M KCl) during islet 
experiments.  The 127 µm platinum working electrode was coated with a layer of Nafion 
(perfluorosulfonic acid-PTFE copolymer, 5% w/w solution in ethanol).  This electrode 
was held at -0.45 V vs. Ag/AgCl (2 M KCl) during islet experiments 
The capsule containing the islets was then placed in the MAMP, and the 
Cytosoft® data collection and pump control program started.  The islets were allowed to 
equilibrate for 20 minutes in the MAMP at 37 ºC at a flow rate of 20 µL/min, before data 
collection of insulin commenced.  The pump cycle for islet experiments was 180 seconds, 
with 140 seconds at flow rate of 20 µL/min and a 40 second stop flow period.  To 
validate that the sensor can detect glucose stimulated insulin secretion, islets were 
initially perifused with HBSS with 2.8 mM glucose, referred to as low glucose.  After 45 
minutes, the perifusion media was switched to HBSS with 16.7 mM glucose, referred to 
as high glucose, for 42 minutes.  The media was switched back to low glucose for 33 
minutes, to high glucose for 66 minutes, and then back to low glucose.   
Identical procedures were followed in the absence of islets to determine the effect 
of increased glucose levels on the sensor.   
Potassium stimulated insulin secretion was also studied. In these experiments, 
islets were initially perifused HBSS with low glucose for 45 minutes, HBSS with high 
glucose for 45 minutes, HBSS with low glucose for 30 minutes, HBSS with high glucose 
for 45 minutes, HBSS with low glucose for 30 minutes, HBSS with 2.8 mM glucose 
supplemented with 50 mM potassium for 48 minutes, and then returned to HBSS with 
low glucose.    Identical procedures were followed in the absence of islets to determine 
the effect of increased glucose levels on the sensor. 
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Results and Discussion  
We present the development of a MWCNT/DHP composite film and its use in a 
microfluidic chamber inside the MAMP, yielding a sensor capable of detecting insulin 
secretion from islets and study of islet metabolism as a whole. This film was compared 
with established electrochemical insulin sensors based on MWCNTs, namely the 
MWCNT film cast from DMF of Wang and Musameh126 and the MWCNT/dihexadecyl 
phosphate composite films of Wu et al.128  As this sensor has been designed for use in the 
MAMP, uniformity of coating and adherence of the film to the electrode surface are vital.   
 Figure 27 presents a preliminary comparison of these three film types.  CVs were 
obtained in buffer (pH 7.4, 0.02% v/v Tween-80) as background and in insulin solutions 
(72.5 µM) prepared in the same buffer.  As displayed in Figure 2A, a representative CV 
using the MWCNT film cast from DMF shows an irreversible oxidation peak at +0.759 V 
vs. Ag/AgCl, 2 M KCl, which is well resolved from the background buffer.  The CV 
using the MWCNT/dihexadecyl phosphate film, solid line in Figure 2B, has an oxidation  
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Figure 27. Cyclic voltammograms in 50 mM phosphate buffer (pH 7.4, 0.02% v/v 
Tween-80) and 72.5 µM insulin solutions in the same buffer at a 3.0 mm GCE coated 
with each film type vs. Ag/AgCl (2 M KCl). Scan rate: 50 mV/s. (A) MWCNT cast from 
DMF; (B) MWCNT/dihexadecyl phosphate electrode; (C) MWCNT/DHP electrode. 
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peak at +0.753 V vs. Ag/AgCl, 2 M KCl, and is not as well defined as the insulin 
oxidation peak for the MWCNT film cast from DMF or the MWCNT/DHP film.  
Because of the decreased magnitude of the insulin oxidation peak, the 
MWCNT/dihexadecyl phosphate film is the least desirable choice for use in insulin 
detection.  The oxidation peak of insulin for the cyclic voltammogram of the 
MWCNT/DHP composite film, solid line in Figure 2C, has a peak potential of +0.765 V 
vs. Ag/AgCl, 2 M KCl, and is well defined compared to the background voltammogram 
in buffer (dotted line).  The average peak current as a function of insulin concentration 
for cyclic voltammograms of each film is given in Table 2.  
 
Table 2.  The insulin oxidation peak currents from cyclic voltammograms of 1 mm GCEs 
modified with MWCNT cast from DMF, MWCNT/dihexadecyl phosphate films, and 
MWCNT/DHP films and the ratios of the peak current to the insulin concentrationa 
 
aCVs were run with scan rate of 50 mV/s and a Ag/AgCl (2 M KCl) reference electrode 
in insulin solutions in 50 mM phosphate buffer (pH 7.4, 0.02% v/v Tween-80).  At least 
three CVs were obtained for each film type. 
 
 The electron transfer kinetics, as indicated by the oxidation peak current divided by the 
insulin concentration, ip/C, for the MWCNT film cast from DMF and the MWCNT/DHP 
composite film, were improved compared with the values for the MWCNT/dihexadecyl 
phosphate film.  All three films show oxidation at similar potentials (Table 2), with the 
sensitivity of the MWCNT/dihexadecyl phosphate film being the lowest.  The large 
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standard deviations in the peak current values in Table 2 result from each film being hand 
cast. For this reason, each film must be calibrated individually prior to any experiments 
that involve insulin detection.  By comparing the oxidation peak current as a function of 
concentration, it is clear that the MWCNT/DHP film and the MWCNT film cast from 
DMF have the best current response and kinetics and thus are the best leads for the 
detection of insulin from physiological samples; however, further testing is necessary to 
determine which film was most suitable for the microfluidic environment of the MAMP. 
To determine the resistance to shear force of these three film types under the 
microfluidic flow conditions of the MAMP, sensor head GCEs (Figure 26) were coated 
and tested under identical conditions.  Representative films for each film type are shown 
in Figures 28A-C before testing and in Figures 28D-F after testing. Prior to testing in the 
MAMP, all three films appear to have complete surface coverage with some surface 
roughness seen in the MWCNT/dihexadecyl phosphate and MWCNT/DHP films.  After 
4.5 hours in the MAMP under stop flow conditions with 180 s cycles with a flow rate of 
20 µL/min for 140 s and a 40 s stop flow period, the thicknesses of the MWCNT film 
cast from DMF and the MWCNT/dihexadecyl phosphate film, Figure 28D and 28E, are 
clearly reduced. The adherence and integrity of the films were compared by using the 
pre- and post-testing images and visually inspecting the optical density of the film 
remaining as the percentage of its original area.  The ratio of the remaining film to the 
area of original film is defined as the percentage of film loss.  The MWCNT film cast 
from DMF lost 53.6% of its original coverage.  The loss of the MWCNT/dihexadecyl 
phosphate film was more dramatic, with a loss of 90.2% of the original film area. In  
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Figure 28.  (A-C) Optical microscope images of MWCNT films on modified sensor head 
(A) Cast from DMF, (B) MWCNT/dihexadecyl phosphate, and (C) MWCNT/DHP      
(D-F): Same films after 4.5 hours of testing in the MAMP (D) Cast from DMF, (E) 
MWCNT/dihexadecyl phosphate film, and (F) MWCNT/DHP film. 
 
 
 
comparing Figures 28C and 28F, visual inspection showed that none of the 
MWCNT/DHP film was lost, although some surface changes were observed. The 
MWCNT/DHP film maintained its integrity and had the best adherence to the electrode 
surface during the pulsed stop flow conditions in the MAMP out of the three film types 
tested.  The MWCNT film cast from DMF and the MWCNT/dihexadecyl phosphate film 
are only physisorbed onto the electrode surface, while MWCNT/dihexadecyl phosphate 
film shows increased homogeneity of the MWCNT film resulting from the addition of a 
fatty acid to the suspension.  In the case of the MWCNT/DHP film, there is physical 
crosslinking of the nanotubes from the self-polymerization of DHP.130  Therefore, 
although the MWCNT/DHP film and the MWCNT film cast from DMF showed similar 
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ip/C values (Table 2), the MWCNT/DHP film is best suited for use in the MAMP as it 
can better withstand the fluidic shear forces of the instrument, and consequently was used 
in all future experiments.   
LSVs of the MWCNT/DHP composite film were also obtained in the MAMP to 
verify that the MWCNT/DHP composite film on the 1 mm glassy carbon electrode of the 
sensor head still has the ability to electrochemically detect insulin in a microfluidic 
system similar to the preliminary tests of Figure 27.  Sample LSVs of the MWCNT/DHP 
composite film on the glassy carbon electrode of the modified sensor head in buffer and 
300 µM insulin are shown in Figure 29.  In the presence of insulin, a peak appears around 
+0.81 V vs. Ag/AgCl, 2 M KCl demonstrating the oxidation of insulin at the 
MWCNT/DHP composite film on the GCE of the modified sensor head in a microfluidic 
device.  This experiment indicates that the MWCNT/DHP film preserves electrochemical 
activity in the MAMP (Figure 29) similar to that of preliminary experiments (Figure 27). 
  
 
Figure 29.  Linear sweep voltammograms of 300 µM insulin in 50 mM phosphate buffer 
(pH 7.4, 0.02% v/v Tween-80) and of blank buffer at a 1 mm GCE on the modified 
sensor head coated with MWCNT/DHP composite film vs. Ag/AgCl (2 M KCl) in the 
MAMP. Scan rate: 50 mV/s 
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Amperometric calibrations were performed on MWCNT/DHP films at +0.88 V 
vs. Ag/AgCl, 2 M KCl on both 3 mm GCEs in solution under moderate stirring and the 1 
mm GCE of the modified sensor head in the MAMP.  The blank and insulin solutions 
were in 50 mM phosphate buffer (pH 7.4, 0.02% v/v Tween-80).  The current increase as 
a function of insulin concentration is given in Figure 30A for three distinct 
MWCNT/DHP sensor films on a 3 mm GCE, with each point on the graph representing 
twenty seconds or 200 collected data points.  The similarity of the slopes for these three 
calibrations, given in the equations in Figure 30A, suggests that the sensitivity of the 
films is comparable, indicating the reproducibility of these films.   
 
 
Figure 30. Insulin calibration curves of MWCNT/DHP films at + 0.88 V vs. Ag/AgCl (2 
M KCl).   (A) Calibration curves of three different films on 3 mm GCEs (B) Calibration 
curve of a single film on a 1 mm GCE of a modified sensor head in the MAMP  
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An amperometric calibration of the MWCNT/DHP film in the MAMP was 
performed to ensure that the limit of detection is within the expected physiological 
concentration range.  The current increase during flow as a function of insulin 
concentration increase is given in Figure 30B.  Each calibration point on the graph 
represents at least five stop flow cycles, comprising 700 collected data points.  Each film 
must be calibrated individually to account for variation in electrode coating due to 
manual handcasting of the MWCNT/DHP suspension.  The current increase for the blank 
of buffer (0 µM insulin) was not visible above the peristaltic noise of the sensor.  The 
presence of the large y-axis intercept in Figure 30B is due to the same peristaltic pump 
noise.  We were able to detect changes in insulin concentration as low as 1 µM during 
calibration experiments, which falls within the expected physiological range.  As there 
are no literature values for the secretion of insulin from islets of male FVB mice, for 
comparison purposes the values determined in Bergsten’s study of individual islets 
isolated from ob/ob- mice were used.  Insulin was measured using perifusion assay with 
subsequent quantitation using ELISA, where insulin release of 3 + 1 pmol g-1 s-1 was 
observed when the glucose concentration was 3 mM with an increase to 99 + 10 pmol g-1 
s-1 upon stimulation with 16 mM glucose.104 By extrapolating this data using the reported 
islet weight range of 8 – 15 µg and the MAMP volume of 3 µL, approximately 75–125 
islets, and stop flow of 40 seconds, a concentration range of 24–75 nM could be expected 
at the end of the stop flow period for low glucose and a range of 0.8–2.5 µM for high 
glucose. While this value is for ob/ob- mice, it is expected that the value could be larger 
for the FVB mice used in our studies, as islet function is impaired in ob/ob- mice. 
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Figure 31. Typical flow – stop flow amperometric current profile of a MWCNT/DHP 
sensor film in MAMP at + 0.88 V vs. Ag/AgCl (2M KCl) showing the pump on/off 
periods, peak current (ip) and peristaltic pump clamping spike. 
 
 
  
To demonstrate the suitability of the MWCNT/DHP film in the MAMP for 
studying insulin with physiological samples, the response of the sensors in the presence 
of islets was measured.  Figure 31 shows the amperometric current/time profile of a 
MWCNT/DHP composite film electrode during a typical stop-flow period in the presence 
of insulin secreting islets and the dynamics of the signal upon restart of flow.  Also 
visible in Figure 6 is the spike in current corresponding to the perturbation in microfluidic 
flow caused by the peristaltic pump clamping.  The shape of the current-time profile is 
the result of convective mass transfer during flow as well as decreased mass transport 
resulting only from diffusion during stop flow, when the secreted insulin must diffuse to 
sensors across the 100 µm gap of the microfluidic chamber.  The peak height (ip), which 
was used in data analysis, is measured from convective flow steady-state current to the 
minimum of the stop flow diffusional current as shown in Figure 31.  One reason for 
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using ip in data analysis is that the stop flow data has a higher signal to noise ratio and 
lower detection limits than the convective flow data even after filtering out the high 
frequency noise of the peristaltic pump from flow data.  The current at the sensor during 
stop flow is linear when graphed vs. t-1/2, indicating that the time dependence profile of 
the insulin release results from diffusional mass transport from the cells to the sensor.  
This will be the focus of future studies and could likely be modeled as a two electrode 
system as analyzed by Bard and Faulkner.33  Currently, peak height at the end of the stop 
flow phase is the most accurate way to analyze the insulin sensor data with islets as it 
represents the maximum physiological activity measured during the stop flow period.   
Confirmation of the detection of glucose stimulated insulin secretion from 
pancreatic islets is demonstrated in Figure 32, which shows the raw amperometric current 
response of the MWCNT/DHP sensor film in the presence of islets with 2.8 and 16.7 mM 
glucose.  In this experiment, switching the glucose concentration in the HBSS media 
from low (2.8 mM) to high (16.7 mM) was used to stimulate insulin secretion by the 
islets.  
 
 
Figure 32.  Amperometric current response MWCNT/DHP sensor film in MAMP with 75 
islets at + 0.88 V vs. Ag/AgCl (2M KCl) showing increase in peak currents upon 
stimulation of islets with 16.7 mM glucose. 
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Figure 33. Insulin concentration (background subtracted) as measured with 
MWCNT/DHP composite film in the MAMP with islets upon stimulation with high 
glucose  
 
 
The stop flow peak current in the absence of islets exhibits no significant change 
(7.8 ± 6.3 %) when the glucose concentration of the HBSS media is increased from 2.8 
mM to 16.7 mM.  The background current observed at the MWCNT/DHP composite film 
electrodes differed, due to variability arising from hand-casting of the films.  Due to this 
variability, and the fact that insulin secretion is extremely low on the micromolar scale 
during exposure to low glucose,104 this background current was subtracted.   The 
sensitivity of the MWCNT/DHP film determined in Figure 30 B was used to convert the 
background subtracted current to concentration.  
As shown in Figure 33, when islets are present in the MAMP, the insulin 
concentration was 3 ± 3 µM during exposure to 2.8 mM glucose.  The insulin 
concentration increases rapidly to 106 ± 5 µM when the glucose concentration is 
increased to 16.7 mM glucose. When the glucose concentration returns to 2.8 mM, the 
insulin concentration returns to 3 ± 5 µM.  A second exposure to 16.7 mM glucose  
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Figure 34. Insulin concentration (background subtracted) as measured with 
MWCNT/DHP composite film in another chamber of MAMP with islets upon 
stimulation with high glucose 
 
 
increases the insulin concentration to 104 ± 9 µM, with a decrease to 3 ± 3 µM upon 
return to 2.8 mM glucose. 
The stop flow current response at the MWCNT/DHP sensor for an additional 
chamber of islets is shown in Figure 34.  Again an increase in the insulin concentration is 
seen upon stimulation with 16.7 mM glucose, from 6 ± 7 µM to 67 ± 9 µM.  The 
concentration decreases to 0 ± 7 µM when the glucose concentration is returned to 2.8 
mM.  A second exposure to 16.7 mM glucose causes the insulin concentration to increase 
to 104 ± 10 µM, with a return to 10 ± 14 µM insulin concentration when the glucose 
concentration is lowered to 2.8 mM. This larger signal upon a second stimulation with 
16.7 mM glucose could be indicative of time dependent potentiation (TDP) that is 
characteristic of β cells in which the pool of insulin granules available for immediate 
release is expanded by a prior exposure to glucose.83 For both chambers of FVB murine  
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Figure 35. Normalized baseline current response at the lactate oxidase electrode in 
microfluidic chamber of MAMP upon stimulation of 75 islets with high glucose 
 
 
islets the increase in the concentration of insulin secreted upon stimulation with glucose 
is much greater than the concentration increase seen for ob/ob- mice in literature, which 
was measured using perifusion with ELISA quantitation104 and is greater than the eight-
fold increase seen with isolated rat islets.139 
In the same chamber of islets as Figure 33, increases are seen in the current at the 
lactate oxidase during flow each time the islets are stimulated with 16.7 mM glucose, as 
shown in Figure 35.  This is significant because it has been shown that up to 90% of the 
pyruvate produced within β cells is shuttled through the TCA cycle. In the other cell 
types of the islet (α, δ, and PP cells), only 15% of pyruvate undergoes mitochondrial 
metabolism. For this reason, the majority of lactate released from the islet is not derived 
from the β cells but rather from the α, δ, and PP cells.140  Thus, the increase in current at 
the lactate electrode during glucose stimulation suggests that we are successfully able to 
observe the metabolic activity of the entire islet, not just that of β cells. 
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At +0.88 V vs. Ag/AgCl (2 M KCl), the potential where insulin is detected with 
the MWCNT/DHP composite film, somatostatin is a possible interferent as it is secreted 
by the δ-cells of the islet92 and has a peak oxidation potential of +0.80 V vs. Ag/AgCl.141 
The dramatic increases seen at the MWCNT/DHP composite electrode in Figures 33 and 
34 are unlikely to be due to somatostatin as β cells are stimulated to secrete insulin when 
islets are exposed to high levels of glucose83 and the function of somatostatin is to inhibit 
β cells.142,143 
A major benefit of our MAMP protocol for studying islet metabolism is the 
confined volume into which insulin is released compared with conventional methods.  
This setup enhances the detection of insulin and other metabolites as it allows them to 
accumulate during the stop-flow period.  If the MWCNT/DHP composite film insulin 
sensor was utilized outside of the MAMP stop-flow system, this benefit would be lost 
and the concentration detected from the same number of islets would be lower.  While 
this concentration is easily measured, if necessary, the stop flow period could be 
lengthened to allow insulin to accumulate and increase the sensitivity of the technique, 
enabling the use of a smaller number of islets.  
The effect of potassium stimulation on isolated murine islets was also studied 
using the MWCNT/DHP composite electrode in the MAMP.  The background subtracted 
insulin concentration response of three chambers of islets can be seen in Figure 36A-C.  
In all three cases,  the insulin concentration increases during exposure to 16.7 mM  
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Figure 36A. Insulin concentration (background subtracted) as measured with 
MWCNT/DHP composite film in the MAMP with 75 islets upon stimulation with high 
glucose and low glucose with 50 mM potassium 
 
 
 
 
Figure 36B. Insulin concentration (background subtracted) as measured with 
MWCNT/DHP composite film in the MAMP with 75 islets upon stimulation with high 
glucose and low glucose with 50 mM potassium 
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Figure 36C. Insulin concentration (background subtracted) as measured with 
MWCNT/DHP composite film in the MAMP with 75 islets upon stimulation with high 
glucose and low glucose with 50 mM potassium 
 
 
 
glucose with a smaller, reversible increase seen upon exposure with HBSS containing 2.8 
mM glucose and 50 mM K+.  This smaller, yet significant increase, agrees with insulin 
secretion results for isolated rat islets measured via radioimmunoassay.139  
These islet studies demonstrate the detection of insulin secreted by islets with our 
newly developed MWCNT/DHP composite sensor in the MAMP as a real-time method 
for characterizing islet function and physiology in microfluidic devices.  The previous 
studies of rat islets mentioned for glucose stimulated insulin secretion and potassium 
stimulated secretion, as well as the study of the role of pyruvate in β cells, was not real-
time methods but rather standard static methodology that required subsequent analysis of 
insulin content by radioimmuoassay.139  Bergsten’s study of isolated islets from ob/ob- 
mice was performed using a perifusion method with ex situ analysis of insulin via 
ELISA.104  The addition of insulin sensing capabilities to the MAMP have a clear 
advantage for studying islet physiology as the metabolic activity of the islet as a whole 
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can be studied in addition to insulin secretion.  The MWCNT/DHP composite sensor has 
been used in the MAMP for studies of islet physiology under continuous flow to study 
oscillations in insulin secretions.73  The sensor has also been adapted for use with a 
carbon fiber ultramicroelectrode to enable measurements of insulin secretion from single 
islets.144 
 
Conclusions 
Combined with our successful detection of glucose stimulated insulin secretion 
and the increased islet metabolism that corresponds with that, these results of potassium 
stimulated insulin secretion show that the addition of the MWCNT/DHP sensor into the 
MAMP has enabled real-time study of islet metabolism, including insulin secretion and 
lactate production.  We have successfully developed a MWCNT/DHP composite film 
electrode for the electrochemical detection of insulin secreted by islets in a microfluidic 
system.  This sensor enables direct label-free detection of insulin with improved 
electrocatalytic kinetics, facile preparation, and resistance to fluidic shear forces as 
compared to other insulin sensors.  We were able to detect insulin concentrations as low 
as 1 µM in the MAMP during calibration experiments.  This sensor was integrated into 
the multianalyte microphysiometer, and insulin secretion by islets was detected.  The 
increase in concentration of insulin detected for 75 islets is much higher than the limit of 
detection and as high as 100 µM for the sensor because of the confined volume of the 
microfluidic chamber and the buildup of insulin molecules during a stop flow period.  
Additionally, increased insulin secretion in response to potassium stimulation was also 
observed.  The MWCNT/DHP composite sensor will be used in the MAMP to study islet 
71 
physiology in a constant flow method to attempt to observe the oscillations in insulin 
secretion typical of islets. This MWCNT/DHP composite sensor will be also used with a 
carbon fiber ultramicroelectrode to study insulin secretion from single islets via scanning 
electrochemical microscopy.    
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CHAPTER V 
 
MAMP FOR THE STUDY OF THE  
METABOLIC EFFECTS OF CHOLERA TOXIN 
 
Introduction 
Cholera is a potentially life-threatening infectious secretory diarrhea caused by 
cholera toxin (CTx) that is secreted by the gram negative bacterium Vibrio cholera.145,146  
The seventh cholera pandemic that still continues today began in the 1960s when the El 
Tor strain of cholera emerged as the most prevalent form of the disease.145-147  This strain 
entered the Western hemisphere in 1991 in Peru and has since caused more than a million 
cases in Central and South America.146  The only animal reservoirs of V. cholerae are 
shellfish and plankton, and infection can be caused by drinking contaminated water or 
food.145,146 Those vibrios that survive passage through the stomach can adhere to the 
mucosal surface of microvilli of the small intestine where they secrete cholera toxin145,146 
as well as other toxins.147  The concentration of vibrios on the mucosal surface rapidly 
increases to 107 to 108 cells per gram of tissue. 
After an incubation period that can vary from 6 hours to five days, the onset of 
symptoms is abrupt and is characterized by severe diarrhea that can reach a rate of 1 L/hr.    
This fluid contains large amounts of sodium, chloride, bicarbonate, and  
potassium, as well as mucus; the loss of these electrolytes cause blood volume depletion, 
low blood pressure, and shock.145,146,148   The fluid loss can be so great that without proper 
rehydration, death can result within hours of onset.145  
 
73 
 
Figure 37.  Mechanism of action of cholera toxin. [Adapted from Finkelstein]146 
 
 
These clinical effects arise from the action of cholera toxin on both the epithelial 
and nervous cells of the intestine.  The mechanism of action of cholera toxin is illustrated 
in Figure 37. Cholera toxin, 84 kDa AB5 hexameric protein, approaches the target cell 
where B subunits bind to GM1 ganglioside.  Upon a conformational change, the A 
subunit is presented and enters the cell.  The disulfide bond of the A unit is cleaved by 
glutathione, leaving A1 and A2.  The A1 unit then catalyzes the formation of ADP-ribose 
from NAD+.  ADP-ribosylation of G protein Gsα blocks GTP from inactivating adenylate 
cyclase.146  This causes excessive production of cAMP, which triggers an increase in 
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chloride secretion by epithelial cells145 and also triggers changes in secretion by the 
enteric nerves of the intestine.148 
Cholera toxin is a particularly interesting subject for study in the MAMP, as the 
clinical effect is well described145-148 as is the mechanism of adenylate cyclase 
activation,149,150 but there is less information known about the acute and dynamic 
metabolic effects that occur as a result of exposure to cholera toxin.   
As it has been suggested that the diarrheal response to cholera toxin has a 
significant neurological component (up to 50%),149 neuronal cells are a logical choice for 
use in the MAMP.  Additionally, PC-12 pheochromacytoma cells (ATCC # CRL-1721) 
have been shown to be a useful model for studies of neuronal cells151 and to possess GM1 
ganglioside receptors capable of binding cholera toxin.152 
In this chapter, we present the metabolic response of PC-12 cells to cholera toxin.  
In order to explore which metabolic pathways were affected to cause the response 
observed, we varied the concentration, duration, and number of exposures of cholera 
toxin.  Additionally, the metabolic response of PC-12 cells to forskolin was measured, as 
forskolin is known to reversibly activate adenylate cyclase and cause elevated cAMP in 
PC-12 cells.153 The effect of the cAMP-dependent protein kinase inhibitor H-89 on the 
metabolic response to cholera toxin were also studied, as H-89 has been shown to block 
the effect of forskolin on PC-12 cells.153  
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Experimental  
Chemicals and Instrumentation 
All materials were used as obtained unless otherwise noted.  Cholera toxin from 
Vibrio cholerae, forskolin from Coleus forskohlii, H-89 dihydrochloride hydrate, glucose 
oxidase (GOx, Aspergillus niger), bovine serum albumin (BSA, fraction V, 96%), and 
glutaraldehyde (glutaric dialdehyde, 25 wt % solution in water) were purchased from 
Sigma. Stabilized lactate oxidase (LOx) was purchased from Applied Enzyme 
Technology (Pontypool, UK).  Sterile glucose solution and (L)-lactic acid were 
purchased from Fischer Scientific.  Lyophilized alamethicin was obtained from A.G. 
Scientific, Inc. (San Diego, CA).  All MAMP consumables including cell inserts, spacers, 
and membranes were obtained from Molecular Devices Corp. (Sunnyvale, CA).  
Modified sensor heads for the MAMP and enzyme films were prepared as described in 
chapter II.  Modified RPMI 1640 buffer for use in MAMP was purchased from 
Mediatech (Manassas, VA).  
 
MAMP experiments with pheochromacytoma cells 
Pheochromacytoma cells (~5 x 105 per insert, PC-12, CRL-1721 ATCC) were 
seeded in Corning Costar® Transwell® collagen coated cell culture inserts (PTFE, 3 µm 
pores) and allowed to grow overnight in F12K media supplemented with 15% donor 
horse serum and 2.5% fetal bovine serum. All MAMP experiments followed the basic 
procedure described in chapter II. A four channel microphysiometer and Cytosoft® 
program (Molecular Devices) were used to control pump cycles and temperature.  The 
multipotentiostat described in Chapter III was used to measure the current response.  A 
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120 s stop flow cycle was used with 80 s at a flow rate of 100 µL per minute and a stop  
period of 40 s.  In all experiments modified RPMI 1640 media containing 5 mM glucose 
was used. Cholera toxin is sold by Sigma Aldrich as a lyophilized powder that is 
reconstituted as a 23.5 µM solution containing 0.05M Tris buffer salts, pH 7.5, 0.2 M 
NaCl, 0.003 M NaN3, and 0.001 M sodium EDTA.  For this reason, all experiments with 
cholera toxin and controls were run with 5 mM glucose modified RPMI 1640 media 
supplemented to contain the appropriate concentration of these compounds. 
In order to determine the basal metabolic rate of PC-12 cells without toxin, cells 
were allowed to equilibrate for an hour and thirty minutes before treating with 101 µM 
alamethicin for forty minutes. In toxin experiments, the cells were again allowed to  
equilibrate for a period to determine their rate prior to exposure.  The cells were treated 
with toxin for a period of time, and then returned to the running media to allow a period 
of recovery prior to treatment with alamethicin.  In all experiments the sensors were 
calibrated with modified RMPI media with no glucose and no lactate, with 0.05 mM 
lactate and 1 mM glucose, with 0.1 mM lactate and 3 mM glucose, with 0.2 mM lactate 
and 5 mM glucose, and in some cases with 0.3 mM lactate before being returned to the 
running media. Data was analyzed as described in chapter II.   
 
Results and Discussion 
The basal metabolic rates for three chambers of PC-12 pheochromacytoma cells 
from the same passage and cell seeding are given in Table 3. While there was found to be 
variability in the basal metabolic rates between passages and seedings, within a given 
seeding the rates were very similar.  
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Table 3.  Basal metabolic rates of PC-12 cells 
 
 
 
 
Figure 38.  The basal metabolic rates of three chambers of 5 x 105 PC-12 cells as 
measured in the MAMP.  There is no glucose signal in the third graph as that sensor did 
not calibrate properly. 
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For this reason in all toxin experiments, one chamber of cells was used to 
determine the basal metabolism of the cells without exposure to cholera toxin.  The basal 
metabolic rates for three chambers of PC-12 cells are shown within Figure 38.  When 
treatment with 101 µM alamethicin begins at 5040 s, the metabolic rates of all signals 
rapidly decrease as expected for induced cell necrosis.  
The initial experiment performed to determine the metabolic effect of cholera 
toxin on PC-12 cells involved exposing the cells to 1000 nM cholera toxin for 30 
minutes, followed by 90 minutes of recovery before treatment with alamethicin to kill the 
cells.  
When the killed cells were treated 1000 nM cholera toxin, a significant shift was 
seen in the glucose oxidase electrode signal as shown in Figure 39.  The shift in current at 
the glucose oxidase electrode during flow was quantified as the ratio of the shift to the 
pre-exposure value.   These values for three chambers of cells are given in Table 4; while 
the magnitude of the shift in the glucose signal was less for dead cells than live cells, the 
ratio of the shift to the pre-exposure current was the same.   Unfortunately, these results 
indicate that cholera toxin itself is somehow interfering with glucose oxidase.  However, 
even after correcting for this shift, no change was seen in the rate of glucose consumption 
when cells were treated with cholera toxin, even at the highest concentration and longest 
exposure time.  For this reason, the glucose consumption rate is not shown in the results. 
  
 
 
 
 
 
 
 
79 
Table 4.  Effect of 1000 nM CTx on glucose oxidase sensor in three chambers of cells 
 
 
 
 
 
   
Figure 39.  MAMP signals for 5 x 105 PC-12 cells in response to 1000 nM CTx 
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Figure 40.  The metabolic rates of three chambers of PC-12 cells exposed to 1000 nM 
cholera toxin 
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The metabolic rates of three chambers of 5 x 105 PC-12 cells exposed to 1000 nM 
cholera toxin are shown in Figure 40.  During exposure, the oxygen consumption rate 
decreases by 40%; when exposed to cholera toxin, the extracellular acidification rate 
increases rapidly to a plateau of 188% of the pre-exposure rate.  After cholera toxin is 
removed, the extracellular acidification rate remains stable at this value.  During exposure 
after an initial period where the lactate production rate does not change, the lactate 
production rate increases.  This rate continues to increase even after cholera toxin is 
removed to a peak of 187% of the preexposure rate.  After this the lactate production 
steadily declines, until the cells are killed with alamethicin.   
The metabolic rates of two chambers of 5 x 105 PC-12 cells exposed to 500 nM 
cholera toxin for 30 minutes are given in Figure 41.  As in the case of exposure to 1000 
nM cholera toxin, the lactate production and extracellular acidification rates increased 
rapidly, with the extracellular acidification rate plateau at 171% of the preexposure rate 
and the lactate production rate continuing to increase even after there was no longer 
cholera toxin present to a peak of 249% of the pre-exposure rate.   
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Figure 41.  Metabolic response of PC-12 cells to 500 nM CTx 
 
 
 
Based on the dramatic metabolic changes seen in PC-12 cell metabolism upon 
exposure to cholera toxin, the concentration and duration of cholera toxin exposure were 
studied, as well as the effect of multiple exposures.  The metabolic responses of three 
chambers of PC-12 cells to 3 exposures of 1000 nM cholera toxin, with each exposure 
being 2 minutes long, i.e. a single stop flow period, and followed by a recovery period, is 
given in Figure 42.  The metabolic responses for 3 exposures to 100 nM cholera toxin are 
given in Figure 43.  As in 30 minute exposure, extracellular acidification and lactate  
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  \
 
Figure 42. Metabolic responses of three chamber of PC-12 cells to 3 exposures of 1000 
nM CTx with each exposure 2 minutes long 
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Figure 43. Metabolic responses of three chamber of PC-12 cells to 3 exposures of 100 
nM CTx with each exposure 2 minutes long 
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production rates increase and the oxygen consumption rate decreases.  The lactate 
production rate rises to a plateau in Figure 42 where the cells are exposed to 1000 nM 
cholera toxin, as was the case for the 30 minute exposure.  When cells were exposed to 
100 nM cholera toxin for three cycles of 2 minutes each, Figure 43, the lactate production 
peaks and declines as seen in Figure 41 when the cells were exposed to 500 nM cholera 
toxin for 30 minutes.  
However, the metabolic rates do not respond to the second or third exposure; all 
of the change appears to come from the first two minutes exposure.  In order to verify 
this, PC-12 cells were exposed to 100 nM CTx for a single cycle followed by an almost 
four hour recovery period.  The metabolic responses are shown in Figure 44.  The 
extracellular acidification rate increases to a plateau and oxygen consumption shows a 
small decrease.  An increase to a peak is seen in lactate production, as was the case when 
cells were exposed to multiple doses of 100 nM CTx.  In this case, however the lactate 
production rate decreases to below the pre-exposure level for all three chambers of cells 
tested.  
The significance of this experiment was that the same metabolic response was 
seen whether cells are exposed to a single dose of cholera toxin or multiple doses.  Also, 
there was no response to the second or third dose of cholera toxin in the multiple 
exposure experiment.  This agrees with previous studies that showed that the maximal 
response in terms of cAMP production could be achieved with doses of 100 nM.154 For 
this reason our experiments were performed using 100 nM cholera toxin as we wished to 
see the maximal metabolic effect using the lowest concentration.  Based upon these 
results and the fact that cholera toxin causes irreversible stimulation of adenylate  
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Figure 44.  Metabolic responses of three chambers of PC-12 cells exposed to a single 2 
minute dose of 100 nM CTx 
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cyclase,146 we wanted to explore what cellular pathways are responsible for the increase 
in extracellular acidification and lactate production and decrease in oxygen consumption.  
The decrease in oxygen consumption was particularly interesting as a previous study by 
Keusch on the jejunum isolated from rabbits that had been treated with cholera toxin did 
not show a statistically significant change in oxygen consumption.155  Additionally 
Resnick that the effect of cholera toxin on lactate production varies between multiple cell 
types, even though the generation of cAMP was similar.156  In both of these studies, the 
underlying reasons for these metabolic changes were unclear and were not studied in a 
real-time manner with simultaneous detection other metabolites.  It is also significant to 
note that in the study by Resnick, the cell lines tested were not related to the intestine or 
neurons,156 and the study by Keusch did not attempt to distinguish between the metabolic 
activity of cholera toxin on the epithelial and neuronal cells of the jejunum.155     
 
 
 
Figure 45.  Effect of cholera toxin on adenylate cyclase and effect of cAMP on protein 
phosphorylation [Adapted from Voet]40 
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Figure 45 illustrates the effect of cholera toxin on adenylate cyclase and the effect 
of cAMP.  cAMP is one of the main secondary messengers in the cell and acts to regulate 
the phosphorylation of proteins, through the activity of cAMP dependent protein kinase 
(CAPK), also called protein kinase A (PKA), which is involved in the regulation of 
glycogen and lipid metabolism.40   
It is proposed that when PC-12 cells are exposed to cholera toxin, the elevated 
levels of cAMP cause increased activity of PKA.  To investigate this, PC-12 cells were 
treated with 10 µM forskolin, which also has been shown to cause elevated cAMP levels 
in PC-12 cells; the metabolic response to this is shown in Figure 46.   
 
 
 
Figure 46A.  Metabolic responses of a chambers of PC-12 cells treated with 10 µM 
forskolin 
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Figure 46B.  Metabolic responses of a chambers of PC-12 cells treated with 10 µM 
forskolin 
 
The response of PC-12 cells to forskolin was quite different than their response to 
cholera toxin.  During exposure to forskolin, there is no change in the extracellular 
acidification rate of the cells, although when forskolin exposure ends there is a slight 
increase in acidification that returns to the basal level.  Lactate production decreases 
during exposure to forskolin.  After forskolin is removed, the lactate production increases 
briefly before returning to the basal level.  There is no significant change in the 
consumption of oxygen.   
This difference may be explained by the fact that forskolin has secondary 
activities in addition to its effects on adenylate cyclase.  Forskolin has been shown to 
interact with glucose transporters and ion channels,157 which would doubtless lead to 
additional metabolic effects beyond those caused by elevated cAMP. 
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Figure 47.  H-89, N-[2-(p-bromocinnamylamino)ethyl]-5-isioquinolinesulfonamide153 
 
The second approach taken to determine whether the activity of PKA was 
responsible for the metabolic response of PC-12 cells to cholera toxin was to treat cells 
with a PKA inhibitor.  H-89, or N-[2-(p-bromocinnamylamino)ethyl]-5-
isioquinolinesulfonamide shown in Figure 47, was chosen as an inhibitor as it was 
developed to block effects of forskolin on PC-12 cells by inhibiting the activity of PKA 
without affecting the intracellular cAMP levels.153 H-89 inhibits PKA activity to 2% of 
the control activity.158  The metabolic response of PC-12 cells treated with 30 µM H-89 
for 1 hour followed by a single 2 minute exposure to 100 nM cholera toxin is shown in 
Figure 48.  During treatment with H-89, there is a gradual increase in both lactate 
production and extracellular acidification rates and a dramatic decrease in the oxygen 
consumption rate.  Upon treatment with 100 nM cholera toxin, little effect is seen in the 
oxygen consumption rate, and the extracellular acidification rate stabilizes.  Lactate 
production shows an increase to a plateau.   The time it takes the lactate production rate 
to increase is lengthened and the magnitude of the increase is less than in cells that are 
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Figure 48.  Metabolic responses of three chambers of PC-12 cells treated with 30 µM H-
89 and a single two minute dose of 100 nM cholera toxin 
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not treated with H-89.  This result suggests that the increase in lactate production is 
mediated by PKA.  However, H-89 also inhibits a number of additional protein kinases to 
25% or less of their normal activity including MAPKAP-K1b, MSK1, PKBα, SGK, 
S6K1, ROCK-II, AMPK, and CHK1.158,159  For this reason, a more specific inhibitor of 
PKA must be used to prove the link between the metabolic signals seen and increased 
phosphorylation of glycogen.    
Assuming that the glucose consumption rate of the cells remains unchanged, it is 
our hypothesis that the increased activity of PKA as a result of elevated cAMP levels 
triggers increased breakdown of intracellular stores of glycogen and increased glucose-6 
phosphate (G6P), as shown in Figure 49.40  As the G6P level increases, the cell would not 
need to increase glucose consumption to supply its energy needs.  The breakdown of G6P 
to pyruvate would cause an increase in the ratio of NADH to NAD+.  NAD+ is used in the 
citric acid cycle and NADH in homolactic fermentation.40  The higher concentration 
 
 
 
Figure 49.  The role of glycogen breakdown in cellular metabolism [Adapted from 
Voet]40 
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of NADH would result in shunting of more pyruvate into lactic acid production, which 
would in turn increase the extracellular lactate production and acidification rates.  
Additional ways to explore this hypothesis are through culturing in isotopically labeled 
media to label the glycogen stores within the cell or to culture the cells under glucose 
starvation conditions to decrease the amount of glycogen stored within the cell.  
 Future work includes the study of lower concentrations of cholera toxin to 
develop a dose response curve.  Other studies in our lab of the effect of lower 
concentrations of cholera toxin on fibroblasts have show that although the time period 
until onset varies with concentration the magnitude of the metabolic response was the 
same. 
 
Conclusions 
Multianalyte microphysiometry was successfully used to determine the metabolic 
response of PC-12 cells to cholera toxin, which elevates cAMP levels.  Extracellular 
acidification and lactate production rates increased, and oxygen consumption rates 
decreased, when cells were treated with cholera toxin.  While forskolin is also known to 
cause increased cAMP, the metabolic response of PC-12 cells to forskolin did not mirror 
the response to cholera toxin.  When cells were treated with the PKA inhibitor H-89, 
there was a distinct response of the cells to H-89 itself and the response of PC-12 cells to 
100 nM cholera toxin was diminished.  These experiments show that the MAMP is a 
useful tool for determining the acute metabolic effects of biological toxins in real-time 
and for exploring the signaling pathways triggered by exposure to a toxin or other agent. 
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Future work in the study of the metabolic effects of cholera toxin using the 
MAMP will be center on the use of Caco-2 human colon cell line (ATCC # HTB-37) to 
determine whether there is a differential metabolic response to cholera toxin between the 
colon cells and the enteric nerve cells that have been implicated in up to 50% of the 
clinical effects of cholera.149 
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APPENDIX A 
 
DESIGN AND ASSEMBLY OF MULTIPOTENTIOSTAT MODULES 
FOR MULTIANALYTE MICROPHYSIOMETERY 
 
WRITTEN BY EDUARDO LIMA WITH RON REISERER 
 
Due to the large number of quantities to be measured amperometrically in the 
multianalyte microphysiometer, the design of a custom potentiostat was crucial to keep 
the costs of our system low. Each chamber of the MAMP has three working electrodes 
and one counter electrode that need to be controlled by a bi- or multi-potentiostat. 
Because each MAMP instrument has four chambers, four multipotentiostats are required 
per MAMP. Since our goal is to run several units in parallel, it becomes clear that the use 
of commercial potentiostats is not a viable approach. Instead, we opted to build a modular 
potentiostat in which each module or channel would measure analytes (except pH) in one 
chamber of the MAMP. Thus, a four-channel potentiostat connects to a single MAMP, 
whereas an eight-channel potentiostat can measure changes in analyte concentrations on 
two instruments simultaneously.  
Our modular design is quite flexible and allows for easy modifications to expand 
the current capabilities or for use in other applications. The potentiostat is comprised of a 
passive backplane, a chassis, a regulated DC power supply, a configuration card, and up 
to eight bi-potentiostat modules or channels. 
The backplane, which is shown in Figure 50, consists of a 6-layer printed circuit 
board (PCB) board with connectors on both sides. Its main purpose is to provide 
connections between the modules and the configuration card, as well as to deliver power 
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to the modules. On the front side, eight Z-pack 2mm HM, type A (AMP 188834-1) male 
connectors accommodate the mating connector of each of the modules. On the back side, 
two Z-pack 2mm HM, type B (AMP 100669-1) male connectors accommodate the two 
mating connectors of the configuration card. The Z-Pack 2mm HM family of connectors, 
also used in the compact PCI standard, combines high performance, high density and 
robust mechanical features, as well as allows for shielding. Because of the high pin 
density, multi-layer boards are required in order to route all of the signals.  
 
 
Figure 50.  Backplane of multipotentiostat module 
 
The backplane implements 12 parallel power/high-current lines, 12 parallel signal 
lines and 8 individually addressable lines per slot. The two central layers of the PCB are 
ground planes intended to be connected to earth ground and power ground (common), 
whereas the other two inner layers and the two outer layers are dedicated to signal 
routing. Eight holes in the PCB allow for fixing the backplane to the subrack, as 
discussed below. One of these holes is coupled to the earth ground plane, and is usually 
connected to the earth ground pin of the power line EMI filter in the power supply 
module. The central row of each of the 10 connectors is connected to power ground, 
providing a low impedance path for return currents.  
97 
As for the chassis, the potentiostat is housed in a 3U 19-inch subrack (CMA14-
16/90, Vector Electronics & Technology), which accepts ten 1.65”-wide card cages. We 
used either four or eight of these cages (EFP164A66) to encase the multipotentiostat 
modules, and a wider (3.05”-wide) card cage (EFP304A66) to encase the power supply. 
The front plate of the wide cages had to be remade so as to fill the space of two 1.65”-
wide card cages. The subrack was then mounted in a 19-inch tabletop rack 
(RCBS1900513BK1, Hammond Manufacturing). 
We used open-frame dual-output regulated linear power supplies (HBB15-1.5-
A+, Condor), capable of delivering +12V and -12V at 1.7A. The power supplies were 
partly disassembled and the aluminum frame was cut prior to mounting to the card cage. 
The outputs of the power supply and the earth ground are provided to the configuration 
card by a cable with a 4-pin keyed terminal housing at the end. A combination 
rocker/thermal circuit breaker switch (1410-F110-P1F1-W14QE3-1A, E-T-A) placed at 
the front panel of the cage turns on and off the power supply, and thus, the potentiostat.  
Figure 51 shows a picture of the configuration card. It is comprised of a 4-layer 
PCB, in which two Z-pack 2mm HM, type B (AMP 106774-1) female connectors and 
two Amplimite .050 Series II cap header (AMP 2-174339-5) connectors are mounted on. 
The latter provide direct connection between the configuration card and the DAQ card 
via one (four-module systems) or two (eight-module systems) standard National 
Instruments 68-pin shielded cables, avoiding the need for breakout boxes and clumsy 
cable arrangements. The two inner layers of the PCB consist of ground and power planes, 
whereas the two outer layers are dedicated to signal routing. The cable from the power 
supply connects to a right-angle lock header also mounted on the board. 
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Figure 51.  Configuration card 
 
 
The function of the configuration card is to: (i) distribute power to the backplane; 
(ii) route backplane signal lines to the DAQ card and pertinent signal lines of the DAQ 
card to the backplane; (iii) optically isolate digital signals going to and coming from the 
DAQ card; (iv) decouple the potentiostat analog ground from the DAQ card analog 
ground; (v) implement a power-on sequencing scheme for the modules; (vi) implement a 
six-bit data bus with two additional control bits; and (vii) provide control signals to the 
reed relays that connect/disconnect the electrodes to/from each module. The bus handles 
the selection of the sensitivity ranges of the potentiostat channels as well as the saturation 
status and saturation slot number. To keep compatibility with some E-series DAQ cards, 
we only used 8-bit digital I/O, which lead to the to 6-bit bus concept. The use of a 
configuration card considerably simplifies adapting or expanding the design to 
incorporate new features, as it does not require changes in the backplane or —depending 
on the case— in the module cards. It also allows for different types of modules to be 
plugged to the backplane and be properly routed to the DAQ card. 
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Relays K3 and K4 implement the power-on sequencing scheme, in which +12V is 
available before -12V and 5V, in order to ensure proper operation of CMOS analog 
switches present in the modules. K4 also disconnects the 5V supply coming from the 
DAQ board if the dual-output power supply is turned off, thereby completely de-
energizing the configuration card. 
The tri-state buffer (U2) and the tri-state latch (U3) handle the 6-bit data bus. Because 
each bit of digital I/O in the DAQ card is individually configurable either as input or 
output, we assigned bits 6 and 7 as control signals (output always), and bits 0 – 5 as data 
lines. The direction of the latter is set according to the operation intended to be carried 
out (read from the bus or write to the bus). Bit 7 determines whether the DAQ card is 
writing information (low) to the bus or reading data from it (high). It controls the least- 
significant-bit (LSB) output enable pin of U2 and also the relays K1 and K2, which 
generate the signals that command the electrode relays in the modules. K1 is normally 
open, whereas K2 is normally closed, leading to opposite-phase signals. When bit 7 is 
high, U2 enables its LSB outputs, writing data to the bus, and K1 and K2 are energized, 
meaning that the electrodes are connected to the multipotentiostat circuits in the modules. 
These relay control signals are shared by all modules.  
   By means of individually addressable lines, each module outputs a 
saturation status signal, which is fed to one of the inputs of the 8-line to 3-line priority 
encoder (U1). If saturation occurs (i.e. if the counter electrode cannot be driven to the 
voltage required to set the reference electrode at the desired potential and saturates) then 
U1 outputs —in negative logic notation— the highest number of the saturated modules. 
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These three lines together with the enable output line, which indicates whether saturation 
has occurred, are routed to the lower inputs of U2 and are transferred to the data bus 
whenever the output of the buffer is active. (Note that saturation is different from over 
ranging, and is independent of the chosen sensitivity ranges.) 
When bit 7 is low, U2 is in high-impedance state and there are two possible 
situations: (i) the bus is idle, or (ii) the DAQ is writing data to the latch U3. For the latter 
to happen, bit 6, which is only connected to the latch enable pin of U3, must be pulsed 
high. The data stored in U3 sets the sensitivity ranges in the modules. Although the 
modules share the same sensitivity settings, each of the three working electrodes has a 
separate sensitivity control. There are four sensitivity ranges per electrode (1000nA/V, 
100nA/V, 10nA/V and 1nA/V), which are selectable via a pair of bits, totaling six bits. 
Isolation and level translation of digital signals are accomplished by optoisolators 
and transistors. Signals coming from the 5V-logic DAQ card are converted to 12V 
CMOS logic by Opto4 and Q3, as well as by Opto3 and Q4. Signals coming from the 
modules are converted to 5V-logic by Opto1, Q1, Opto2 and Q2.  
In order to avoid ground loops in the analog signal path, we used two precision 
difference amplifiers (U5 and U6). The two inputs of each amplifier are connected to the 
DAQ board analog ground and to either analog output #0 or analog output #1. The output 
of the chips is referred to the power supply ground (common), and not to the DAQ card 
ground. As for the analog inputs, the DAQ card is configured to non-referenced single-
ended mode, meaning that the power ground is connected to one of the inputs of an 
instrumentation amplifier, while the outputs of the potentiostat are connected to the other 
input through an analog multiplexer, both of them present in the DAQ card. Thus, there is 
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no direct connection between the power supply ground and the analog ground of the 
DAQ card. 
Each module implements a multipotentiostat with three working electrodes, 
meaning that two working electrodes have identical potentials referred to the reference 
electrode. Although our modules were tailored to a specific application, it is 
straightforward to modify the design so as to implement a tri-potentiostat or another 
standard configuration, since the core of the circuit is the same. To achieve maximum 
performance and compactness, almost all components in the modules are surface mount 
technology.  
Figure 52 shows a picture of the module.  The op-amp U1 drives the counter 
electrode, while U2 senses the voltage on the reference electrode, closing the feedback 
loop. U1 is a high-speed op-amp with the ability to drive capacitive loads (Analog 
Devices AD817).  Because the electrochemical cell is part of U1’s feedback loop, 
oscillations may occur in some experimental setups, despite the op-amp’s internal 
compensation for capacitive loads. 
 
 
 
Figure 52.  Multipotentiostat module 
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Therefore, additional external compensation is required to stabilize the potentiostat 
circuit over a wide range of electrochemical cells.  
We used an input-lag compensation scheme (Sergio Franco) with four selectable 
resistors and a fixed capacitor, which comprises the quad single-pole single-throw CMOS 
analog switch U10 controlled by a mechanical rotary switch S1, the capacitor C1 and the 
resistors R2, R44, R45 and R46. The idea is to provide different R-C combinations, 
which could stabilize various setups. The tradeoff for stabilization is an increase in high-
frequency noise, which is filtered out at the current-to-voltage (I-V) converter and at the 
voltage gain sections. The values for the capacitor and the resistors were obtained 
empirically, as they were tailored to the modified Cytosensor chambers used in our 
experiments. Different values may be required to obtain optimal performance for other 
configurations. The CMOS analog switch ensures signal integrity, which is harder to be 
obtained by mechanical switches. In this case, a mechanical switch is only used to 
generate the control signals that select the appropriate compensation pole. 
All analog signals pertaining to the electrochemical cell, as well as earth ground, 
are routed to the 6-pin LEMO connector J2 through single-pole single-throw shielded 
reed relays K1 - K6, which are controlled by two signals from the configuration card 
(transistors Q3 - Q8 energize the relays based on these signals). K1 is controlled 
independently of the other relays, which are all activated by the same control signal. If no 
measurement is being taken, K1 is energized, while K2 – K6 are open. This physically 
isolates the electrodes from the circuit, but still closes U1’s feedback loop to avoid 
saturation of the op-amp and eventual damage to electrodes when these are connected to 
the circuit. When an experiment is in progress, K1 opens and K2-K6 are energized.U5, 
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U12 and U15 are low-noise precision operational amplifiers that carry out the I-V 
conversion. Each op-amp has an associated analog switch (U6, U13 and U16, 
respectively) that selects the gain resistor (i.e. the conversion factor) according to the 
control signals coming from the configuration card. The cutoff frequency of the first-
order low-pass filters is set at 7.5 Hz, but can be easily modified by changing the 
associated capacitors, should larger bandwidths be needed. The output of these op-amps 
is further amplified and/or filtered by separate gain stages, comprised of U8, U14 and 
U17. The working electrodes connected to U12 and U15 (glucose and lactate electrodes) 
are kept at virtual ground, whereas the one connected to U5 (oxygen electrode) is set at 
Vc2-Vc1, where Vc1 and Vc2 are the input (control) voltages of the potentiostat. The 
precision difference amplifiers U3 and U4 compute this voltage, which is applied to the 
positive input of U5. In order to avoid using many large-valued resistors, we opted to 
utilize a T-network configuration to achieve higher sensitivities. However, because the 
desired output of U6 is not referenced to ground (U7 yields the corrected output), the T-
network can not be used in the I-V converter of the independent working electrode. The 
inputs of U5, U12 and U15, as well as of U2, are all guarded to minimize signal 
degradation. Because the current levels involved in the MAMP are quite low, we did not 
implement an iR compensation scheme. 
The voltage at the counter electrode is constantly monitored by a window detector 
circuit, which is implemented by half the quad comparator U9. Q1 acts as an 
inverter/level translator, while Q2 controls the charge and discharge of C15, providing a 
timer mechanism. Should the voltage approach the saturation limits of U1, the output of 
the window detector switches to low, driving Q2 to cutoff and allowing C15 to charge. 
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When the voltage across this capacitor reaches the Schmitt trigger U11’s low threshold, 
the output of the latter switches to logic 0 and remains on this state. When U1’s output 
returns to the non-saturation zone, Q2 discharges C15 through R20 and, after a few 
seconds, the output of U11 goes to logic 1. This signal is monitored by the priority 
encoder located at the configuration card, which detects a saturation state and identifies in 
which channel it has occurred. The timer mechanism ensures that the LabVIEW software 
has enough time to detect the occurrence of saturation in one of the channels. 
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APPENDIX B 
 
MULTIPLE APPROACHES TO MODELING CURRENT RESPONSES IN 
THE MAMP TO DERIVE METABOLIC RATES 
 
There are currently three separate efforts underway to develop models to derive 
metabolic rates from the current responses in the MAMP.  The first effort is lead by 
Narcisse N’Dri, Sebastian Eluvathingal, and Mark Stremler, formerly of Vanderbilt and 
now in the Engineering Science and Mechanics department of Virginia Polytechnic 
Institute and State University.  They used their fluid mechanics specialization to develop 
a 2D axi-symmetric numerical model.160 
 
 
 
Figure 53. Geometry of the 2D axi-symmetric problem. a) Enzyme sensor and b) Oxygen 
sensor 
 
 
Momchil Velkovsky has developed an analytical model for extracting the lactate 
and glucose fluxes of cells.  He has developed formulas for boundary conditions at the 
surface of the electrodes (Eq. B1) and for the electrode current (Eq. B2) that can be 
applied to any solution problem containing cell fluxes.161   
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  Eq. B1 
 
  Eq. B2 
 
 
Jerry Keil has developed a method for derivation of the kinetic rate constants of 
cellular metabolism by modeling the data as a pseudo Cottrell step.  In the MAMP, a  
linear decrease in the observed current at the lactate oxidase electrode versus the inverse 
square root of time proportional to the bulk concentration of analyte confirms the Cottrell 
mechanism; i.e. 
 id = nFAD1/2CO/(πt)1/2 Eq. B3 
 
Here, n equals the number of equivalents per mole; F, the Faraday constant; A, 
the working electrode area, in cm2, D, the diffusion coefficient of lactate, in cm2/s; CO, the 
bulk concentration, in mol/cm3 and t, time in seconds.   This relationship is modified to 
reflect the time dependent kinetic factors of consumption or production (Eq. B4-B5).162 
 t1/2 id(t) = (nFAD1/2CO/π1/2 )  + (nFAD1/2kKIN /aπ1/2 ) t Eq. B4 
 t1/2 id(t) = (nFAD1/2CO/π1/2 )  - (nFAD1/2kKIN /aπ1/2 ) t Eq. B5 
This model was found to be most effective in the middle of the stop flow period 
where the effects of turbulent flow and nutrient depletion are both minimized. 
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